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ABSTRACT
Heinzman, Christina MSN, DNP, Wright State University-Miami Valley College of
Nursing and Health/University of Toledo, 2018. The Role of Antibiotic Therapy in the
Treatment of Small Bowel Bacterial Overgrowth in the Pediatric Population with Short
Bowel Syndrome.
Short bowel syndrome is the congenital or surgical alteration of the small bowel resulting
in a shorter than normal length of small bowel. This condition affects approximately
20,000 people in the Unites States and is diagnosed in 3-5 times per 100,000 live births
annually. Patients with short bowel syndrome are at risk for the development of small
bowel bacterial overgrowth, a serious consequence caused by overgrowth of bacteria in
the small bowel resulting in symptoms of abdominal pain, abdominal distention, feeding
intolerance, malabsorption, weight loss and increased risk of metabolic acidosis. Clinical
studies assessing the role of antibiotic therapy in the pediatric population are nearly nonexistent forcing clinicians to rely on adult literature for guidance. Diagnostic testing
methods are often invasive and difficult to perform in pediatric patients leaving clinicians
to diagnosis this condition based on symptomology. Treatment is often prescribed based
on clinical experience and published expert opinion. Inconsistency in the diagnosis and
medical treatment of small bowel bacteria overgrowth is problematic and warrants further
investigation. The purpose of the evidence-based project was to establish the role of
antibiotic therapy in the treatment of small bowel bacterial overgrowth in pediatric
patients with short bowel syndrome. A one-year retrospective chart review of pediatric
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patients admitted to the Gastroenterology/Lumen service at Cincinnati Children’s
Hospital Medical Center between 5/1/2016-5/1/2017 was conducted. Final analysis of
the data revealed inconsistency in antibiotic prescribing, however, the effectiveness of
treatment was inconclusive due to lack of provider documentation. As a result of the
findings, a best evidence statement (BESt) has been drafted for publication throughout
the institution with the intent to standardize antibiotic prescribing practices for this
population. Developing initiatives that stemmed from this evidence-based practice
project include improved diagnosis by means of DNA mapping, revisions to nursing
standards for central line care in patients with an ostomy, and a poster presentation at a
national conference.

iv

TABLE OF CONTENTS
I.

Page
PROBLEM STATEMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Description of short bowel syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Classification of short bowel syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Definition of small bowel bacterial overgrowth . . . . . . . . . . . . . . . . . . . . 3
Prevalence of small bowel bacterial overgrowth . . . . . . . . . . . . . . . . . . . 3
Risk factors for small bowel bacterial overgrowth . . . . . . . . . . . . . . . . . . 4
Signs and symptoms of small bowel bacterial overgrowth . . . . . . . . . . . . 6
Clinical consequences of small bowel bacterial overgrowth . . . . . . . . . . . 7
Diagnosis of small bowel bacterial overgrowth . . . . . . . . . . . . . . . . . . . . 10
Purpose Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Evidence-based Practice Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
PICOT question . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

II.

EVIDENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Critical appraisal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Clinical knowledge gaps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Statement of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

III.

IMPLEMENTATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Project setting and population . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
IRB determination and HIPAA compliance . . . . . . . . . . . . . . . . . . . . . . 31

v

Implementation plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Identification of resources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Project implementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Stakeholders and facilitators to implementation . . . . . . . . . . . . . . . . . 37
Anticipated barriers to implementation . . . . . . . . . . . . . . . . . . . . . . . . 38
Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Outcome measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
III.

FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Demographics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50
Risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Antibiotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Outcome questions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 53

V.

DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61

REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73

vi

APPENDICES
A.

Database search/keywords . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73

B.

LEGEND Table of Evidence Levels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74

C.

Examples of LEGEND critical appraisal forms . . . . . . . . . . . . . . . . . . . . . 75

D.

LEGEND Grading the body of evidence form . . . . . . . . . . . . . . . . . . . . . . 81

E.

LEGEND Judging the strength of a recommendation form . . . . . . . . . . . . 82

F.

Summary of the pediatric literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83

G.

Pediatric literature synthesis table . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

H.

Summary of the adult literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88

I.

Adult literature synthesis table . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90

J.

Completed LEGEND Judging the strength of a recommendation form . . . 91

K.

Agency approval form . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94

L.

Cincinnati Children’s Hospital Medical Center IRB determination letter . 95

M.

Wright State University IRB determination letter . . . . . . . . . . . . . . . . . . . .96

N.

Data collection tool . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97

O.

Risk factors & signs and symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98

P.

BESt document draft . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99

Q.

Project timeline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112

vii

LIST OF TABLES
Table 1.

Page
Project team . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

Table 2.

Explanation of data variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41

Table 3.

Demographic data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51

Table 4.

Prevalence of risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52

Table 5.

Antibiotics prescribed for SBBO . . . . . . . . . . . . . . . . . . . . . . . . . 53

Table 6.

CLA-BSI counts by antibiotic status . . . . . . . . . . . . . . . . . . . . . . 54

Table 7.

Symptom effect on antibiotic treatment . . . . . . . . . . . . . . . . . . . . 55

Table 8.

Relationship between antibiotic use and number of symptoms . . 56

Table 9.

Resolution of symptoms by antibiotic status . . . . . . . . . . . . . . . . 58

Table 10.

Summary of CLA-BSI following antibiotic exposure for SBBO .59

Table 11.

Anatomical factors effect on CLA-BSI . . . . . . . . . . . . . . . . . . . . 60

viii

LIST OF FIGURES
Page
Figure 1.

Adaptation of Model for Evidence-Based Practice Change . . . 15

ix

ACKNOWLEDGEMENT
This project would not have been possible without the guidance and support of many
dedicated individuals over the last several years.
First and foremost, I acknowledge Dr. Tracy Brewer for her unwavering support and
dedication to my DNP journey and this project from day one. She guided me from
interview to proposal to defense, never leaving my side. Her vast knowledge of the
evidence-based practice process is unparalleled and the experiences from her personal
DNP journey make her the perfect mentor and project chair. Her support and words of
encouragement kept me going when I didn’t think I could. Without you, I would not be
here.
I would like to thank my project committee members including Dr. Lisa Jasin and Dr.
Tonya Schmitt. Their valuable feedback was important to making this project a success.
Their dedication to my DNP journey is deeply appreciated.
I would like to recognize Mike Bottomley, Senior Statistical Consultant at Wright State
University and personal statistical savior. Your support, dedication and expertise has
been a tremendous blessing to this project. Thank you for turning my thoughts, my
questions, and my data into something that has statistical meaning. You have been
amazing.
I would like to recognize and thank Dr. Conrad Cole for his support and dedication to this
project. His willingness to take a chance on me and provide mentorship has been a true
blessing. I promised that I would do something meaningful, I hope that I’ve made you
proud. To my colleagues, Rebecca, Kristen, Lisa, and Susan - I appreciate you more than
you know. For the many times you have talked me off the ledge when I wanted to quit
and the way you supported me during the countless revisions to my defense – I am
forever indebted to you.
Last, but certainly not least, I would like to acknowledge my husband Ron Heinzman.
He has been my rock throughout this entire journey. He has shown patience when I was
frustrated, compassion when I was suffering, and joy when I was celebrating. Thank you
for always supporting me.

x

DEDICATION
I dedicate this project to the many patients with short bowel syndrome that I have had the
opportunity to care for and learn from over the course of my career. To those that are
still alive and thriving, I am encouraged by your perseverance and determination to live a
full life. I am in awe of your strength even on your hardest days. I strive to live my best
life because of you. To those whom have passed, I am honored to have been a part of
your life. I vow to honor your memory by advancing the practice for those that come
after you. To their families that have shown great resilience in the darkest of times yet
consistently share compassion and allow me to learn, my appreciation runs deep. For
you, I have worked tirelessly on this project in hopes that it makes a difference in your
world.
I also dedicate this project to my family; my husband Ron Heinzman, my children
Matthew Heinzman and Blake Heinzman, and my parents Chuck and Teresa Lucas who
have always supported and encouraged me throughout all of my personal and academic
endeavors. You inspire me to achieve the impossible.

xi

I.

PROBLEM STATEMENT

Pediatric patients with short bowel syndrome are at increased risk for the
development of small bowel bacterial overgrowth (SBBO), a serious consequence
characterized by an overgrowth of bacteria within the lumen of the small bowel.
Literature regarding the role of antibiotic therapy to treat SBBO in pediatric patients is
limited and mostly consists of expert opinion and case reports. Due to the lack of clinical
research and standard guidelines for treatment of SBBO in pediatric patients with short
bowel syndrome, care provided within the Division of Gastroenterology, Hepatology, and
Nutrition at Cincinnati Children’s Hospital Medical Center (CCHMC) is variable. The
inconsistency in clinical care and opinions regarding the role of antibiotics to treat small
bowel bacterial overgrowth is problematic. Some providers recommend prophylactic
antibiotics for all patients with short bowel syndrome while some recommend them only
in certain situations. Some providers never recommend prophylactic antibiotics under
any circumstance. Findings from the literature suggest the use of antibiotics in
symptomatic patients (Ching, Gura, Modi, & Jaksic, 2007; Cole & Kocoshis, 2013; Cole
& Ziegler, 2007; Dehmer, Fuller, & Helmrath, 2011; DiBaise, Young, & Vanderhoof,
2006; Malik, Xie, Wine, & Huynh, 2011; Quigley & Quera, 2006; Reed, 2014; Sentongo,
2008; Shah, Day, Somsouk, & Sewell, 2013; Sieczkowska, Landowski, Kaminska, &
Lifschitz, 2016; Vanderhoof, Young, Murray, & Kaufman, 1998; Vanderhoof, Young, &
Thompson, 2003; Youssef, Mezoff, Carter, & Cole, 2012), however experts in the field
are recently moving away from prophylactic use of antibiotics because the risk of
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repeated antibiotic exposure may outweigh the benefits. An evidence-based project was
undertaken to determine the role of antibiotic therapy in the treatment of small bowel
bacterial overgrowth in pediatric patients with short bowel syndrome.
Background
Description of short bowel syndrome
Short bowel syndrome (SBS) is the congenital or surgical alteration of the small
bowel resulting in a shorter than normal length of small bowel. This condition presents
in 3-5 per 100,000 live births per year and there are approximately 20,000 children and
adults currently living in the United States with short bowel syndrome (Cole, Hansen,
Higgins, Ziegler, & Stoll, 2008; Squires et al., 2012). Although this condition can also
occur in adults, this project only focused on the pediatric population.
Short bowel syndrome can occur naturally as a result of a congenital anatomic
anomaly or as a consequence of a surgical procedure. Congenital forms of short bowel
syndrome are caused by deviations in the fetal development of the gastrointestinal tract
such as omphalocele, gastroschisis, or intestinal atresias. Surgical resections of the bowel
may be performed to treat necrotizing enterocolitis, ischemic bowel from malrotation or
volvulus, or stenotic bowel from inflammatory bowel disease (Bhatia & Mundy, 2013).
Those with altered lengths of bowel may suffer from many complications including
intestinal failure with related nutritional deficiencies and malabsorption, altered motility,
abdominal distention, reflux, vomiting, poor growth, dehydration, metabolic acidosis,
accumulation of D-lactate leading to D-lactic acidosis, septic bacteremia, and risk for
overgrowth of bacteria in the small bowel which can escalate the significance of each of
the preceding complications (Xie, 2011).
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Classification of short bowel syndrome
The average length of small bowel for an infant is 250-300 cm compared to 700
cm for the typical adult. The average length of bowel for someone diagnosed with short
bowel syndrome depends on their congenital anomaly or past surgical procedures. Short
bowel syndrome encompasses people who have half or more of their small bowel
resected. Ultra-short bowel syndrome refers to those who have less than 25% of small
bowel remaining.
Definition of small bowel bacterial overgrowth
There is no consensus regarding the definition of small bowel bacterial
overgrowth (Sieczkowska et al., 2016). However, the definition most frequently used
describes SBBO as the presence of >100,000 colony-forming units of bacteria/mL of
luminal aspirate within the proximal bowel (Cole & Ziegler, 2007). The definition has
limited clinical value, as symptoms of SBBO depend on the microbiological composition
of the contaminating microbiota (Sieczkowska et al., 2016). For example, a large number
of gram-positive bacteria from the upper respiratory tract will not have the same clinical
effect as the same number of colonic bacteria growing in the small bowel. This suggests
that a more appropriate definition of SBBO is the presence of >100,000 colonic-type
bacteria grown from a small bowel aspirate (Sieczkowska et al., 2016).
Prevalence of Small Bowel Bacterial Overgrowth
Due to difficulty in performing diagnostic testing in this population, information
regarding prevalence of SBBO is limited. DiBaise et al. (2006) report that little is
actually known about the prevalence; however, in their clinical experience SBBO is
commonly seen. Similar to the DiBaise et al. (2006) study, the Pediatric Intestinal
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Failure Consortium conducted a multi-center retrospective cohort study in 2012 and
found that 76% of the 272 patients reviewed were given oral antibiotics for presumed
overgrowth. Confirmation diagnostic testing was not addressed in their report (Squires et
al., 2012).
There are currently more than 200 patients under the care of the Intestinal Care
Center within the Division of Gastroenterology, Hepatology, and Nutrition at Cincinnati
Children’s Hospital Medical Center. Prevalence of small bowel bacterial overgrowth in
this cohort is not well documented. SBBO has an assigned ICD-10 code, but prevalence
in this group has been difficult to track. This difficulty is related to the often subjective
diagnosis. SBBO is often not listed as a coded diagnosis in the electronic medical record
because generally only the chief symptoms are captured on the patient’s problem list.
Risk factors for Small Bowel Bacterial Overgrowth
Any process that disrupts or alters the microbiota homeostasis of the small bowel
may lead to the development of SBBO (Scarpignato & Gatta, 2013). The microbiota,
commonly known as gut flora, is the complex community of organisms that live in the
digestive tract. DiBaise et al. (2006) and Bohm et al. (2013) catalog the conditions that
are associated with the development of SBBO into three categories including anatomic,
functional, or multi-factorial.
Anatomic conditions that are associated with the development of SBBO include
congenital and acquired abnormalities. Congenital abnormalities include jejuno-ileal
webs, small bowel atresias, gastroschisis, and omphalocele. Acquired abnormalities
include perinatal obstructive conditions as seen in necrotizing enterocolitis, midgut
volvulus, and ischemia. Other acquired anatomic conditions include enterocutaneous
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fistula, duodenal or jejunal diverticulosis, surgically created blind loops, presence of an
ostomy, intestinal strictures, and resection of the ileocecal valve (Cole & Ziegler, 2007;
DiBaise et al., 2006; Malik et al., 2011; Sentongo, 2008). The ileocecal valve is a
muscular sphincter that separates the small intestine and the large intestine. The main
function of the ileocecal valve is to prevent the backwash of colonic bacteria into the
small intestine. Failure of this process due to surgical resection of the ileocecal valve
increases the risk for bacterial contamination into the small bowel and increases the
potential for bacterial overgrowth.
Intestinal dysmotility caused by strictures, adhesions, mucosal inflammation or
exposure of the small bowel to amniotic fluid as seen in gastroschisis are functional risk
factors for bacterial overgrowth (Cole & Ziegler, 2007; DiBaise et al., 2006; Malik et al.,
2011; Scarpignato & Gatta, 2013; Sentongo, 2008). Reflux of bacteria from the colon
into the small intestine combined with poor motility, bowel dilation, and stasis of the
small bowel promote bacterial overgrowth (Ching, Gura, Modi & Jaksic, 2007). Failure
of small bowel clearance due to primary visceral neuropathies or myopathies such as
chronic intestinal pseudo-obstruction (CIPO), megacystis microcolon intestinal
hypoperistalsis syndrome (MMIHS), or radiation enteropathy decrease the phase III
contractions of the migrating motor complex (MMC). The MMC works to sweep the
small bowel every 90-120 minutes to clear it of debris and remnant food. Failure of this
system can lead to stasis and overgrowth of bacteria (Bohm et al., 2013).
Other functional risk factors include the loss of protective gastric barrier as found
in Helicobacter pylori, proton pump inhibitor use, hypochlorhydria, and total or subtotal
gastrectomy (Bohm, Siwiec, & Wo, 2013a; Cole & Ziegler, 2007; DiBaise et al., 2006;

5

Scarpignato & Gatta, 2013). In an otherwise normal physiologic gastric pH environment,
99% of all bacteria in the stomach would be eliminated within 5 minutes (Bohm et al.,
2013). In the absence of gastric acid as found with proton pump inhibitor use, the same
bacterial species can be found in the stomach and in the proximal small intestine (Bohm
et al., 2013).
Immunodeficiency, malnutrition, chronic pancreatitis, and parenteral nutrition
dependency make up the multi-factorial category (DiBaise et al., 2006). Gutierrez et al.
(2012) conducted a retrospective chart review of 57 pediatric patients who underwent
endoscopic evaluation for SBBO and found a strong and independent association
between parenteral nutrition use and incidence of SBBO (p = 0.01). The presence of
SBBO was defined as the presence of >100,000 colony forming units of bacteria/mL of
duodenal aspirate. Given the surgical and medical treatments needed to sustain the life of
a patient with short bowel syndrome, many patients fall into one or more of these risk
categories.
Signs and symptoms of small bowel bacterial overgrowth
Signs and symptoms of SBBO have been described as vomiting or feeding
intolerance, abdominal pain, abdominal distention and bloating, increased flatulence,
diarrhea, steatorrhea, hematochezia, weight loss, malabsorption of fat and carbohydrates,
and metabolic acidosis from the accumulation of D-lactate (Bohm, et al. 2013; Cole &
Ziegler, 2007; Collins & Lin, 2011; de Boissieu, et al., 1996; DiBaise et al., 2006; Di
Stefano et al., 2005; Malik et al., 2011; Reed, 2014). Symptomology and severity of
disease vary widely among individuals. Regardless, each has the potential for negative
health consequences.
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Small Bowel Bacterial Overgrowth Clinical Consequences
Bile acid deconjugation by luminal bacteria leads to fat malabsorption
(Sieczkowska et al., 2016). Fat malabsorption results in the formation of oxalate kidney
stones, steatorrhea, and deficiencies in the fat soluble vitamins A, D, and E. Although
vitamin K is a fat soluble vitamin, deficiency is rarely seen due to the enteric flora’s
natural production of vitamin K. Deficiencies in vitamins A, D, and E can lead to vision
loss, osteoporosis, and neurologic irritability respectively. Deficient vitamins can be
replaced orally, in enteral feeds, or by injection in parenteral nutrition. It is common
practice to replete vitamin deficiencies in pediatric patients when indicated.
Carbohydrate malabsorption can result in D-lactic acidosis, a rare but serious
neurologic condition that occurs in children with short bowel syndrome and SBBO.
Malabsorbed carbohydrates move from the small intestine into the large intestine where
they are fermented into the D-isomer form of lactic acid. Humans cannot metabolize Dlactic acid, so it is absorbed by the large intestine into circulatory system resulting in
elevated serum levels of D-lactate. As a result, patients develop D-lactic acidosis and
exhibit symptoms of hyperventilation, altered mental status, confusion, cerebellar ataxia,
slurred speech, and loss of memory (DiBaise et al., 2006, Sieczkowska et al., 2016).
Serum D-lactic acid is not detected on routine L-lactic acid assays. It is measured using
specialized testing only available at designated reference laboratories. Supportive
biochemical findings for D-lactic acid are metabolic acidosis with increased anion gap
and normal L-lactate concentration (Sentongo, 2008). Impaired carbohydrate absorption
also leads to the production of various gases that result in clinical symptoms of
abdominal bloating, distention, and discomfort.
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Protein malabsorption is not commonly seen in patients with SBBO, but a
reversible form of protein-losing enteropathy has been reported (DiBaise et al., 2006).
Protein losing enteropathy is characterized by the severe loss of serum proteins in the
intestine. In the case of SBBO, it is considered a reversible form of protein losing
enteropathy and resolves as the SBBO resolves. Protein malabsorption can be caused by
the digestion of protein by bacteria or from mucosal damage and loss of absorptive
surface of the small bowel (Sieczkowska et al., 2016).
Increased gastrointestinal permeability associated with SBBO may promote
translocation of enteric bacteria from the gastrointestinal tract into the mesenteric lymph
nodes and visceral organs. Enteric translocation elevates the risk of gut-derived sepsis
(Sieczkowska et al., 2016). Cole et al. (2010) conducted a pilot study of ten infants with
short bowel syndrome and dependence on parenteral nutrition. They found a seven-fold
increased risk of developing a central line associated-blood stream infection (CLA-BSI)
in those who also had SBBO compared to those infants who did not.
Anemia is another clinical consequence of SBBO caused by a combination of
malnutrition, micronutrient malabsorption, competitive bacterial assimilation of nutrients,
and increased losses due to SBBO-associated enteropathy (Sentongo, 2008). Vitamin B12
and folate deficiencies causing macrocytic anemia may result from competitive
consumption of the vitamins by excessive bacterial growth (Sentongo, 2008;
Sieczkowska et al., 2016). Iron deficiency anemia can result from bacterial utilization of
iron. Onset of refractory normocytic anemia in patients with short bowel syndrome or
SBBO should prompt suspicion of multiple micronutrient deficiencies including iron,
vitamin B12, folate and copper (Sentongo, 2008).
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Patients suffering from SBBO often complain of abdominal distention, abdominal
pain, nausea, vomiting and intolerance of gastric feeds. Complications of SBBO can
delay or prevent the weaning of parenteral nutrition. Prolonged use of parenteral
nutrition increases the risk of intestinal failure-associated liver disease (IFALD). It is
estimated that 40-60% of children and up to 85% of neonates on prolonged parenteral
nutrition will develop IFALD (Chan & Wu, 2014). This type of liver disease combined
with loss of central venous access sites due to repeated bacteremia make eventual listing
for a liver transplantation a likely consequence (Xie, 2011).
Quality of life for patients with chronic illnesses have additional stressors that
affect not only the child but extend to their family and caregivers. Stressors can include
loss of time at work, disruption to family schedules and activities, limitations to travel,
and increased responsibilities. Often times these added stressors fall on the primary
caregiving parent while the other maintains employment. A review of literature
regarding quality of life in children with chronic illness was conducted (Kourkoutas,
Georgiadi, & Plexousakis, 2010). By identifying quality of life specific situations for
children, they can be better supported throughout their illness. There are many
instruments that measure quality of life in children with chronic illnesses and are often
used to measure the influence that a certain disease has on the patient and family unit.
When assessing the quality of life, it is important to collect data directly from both the
patient and family when applicable as both are affected.
Failure to recognize signs and symptoms of SBBO can result in delayed treatment
leading to futile attempts to advance enteral feeds, prolonged use of parenteral nutrition
with associated risks for IFALD, extended hospitalizations and increased healthcare
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costs. Spencer et al. (2008) reported a retrospective review of the total charges for 41
patients with short bowel syndrome. The study found that the majority of the $1,028,985
- $1,619,751 spent in the first five years of life were spent during the first year of care
alone and mostly due to hospitalization charges.
Diagnosis of Small Bowel Bacterial Overgrowth
Current diagnostic methods for SBBO include techniques that are invasive and
not feasible in the pediatric population. Diagnostic tests include direct aspirate culture of
small bowel luminal contents, hydrogen breath testing, polymerase chain reactiondenaturing gradient gel electrophoresis and small bowel biopsy. Each method presents
either a technical challenge, prohibitive cost, or the inability to properly assess with
young children (DiBaise et al., 2006; Malik et al., 2011; Xie, 2011).
Direct aspirate culture of small bowel fluid is considered to be the gold standard
in the diagnosis of SBBO, but is often associated with significant limitations (DiBaise et
al, 2006). Aspirate cultures must be collected under general anesthesia during an
esophagogastroduodenoscopy (EGD) procedure, which is not only a technical challenge
and expensive but also places the pediatric patient at risk for potential scope related
perforations and risks associated with anesthesia. The aspirate only gives information for
the area of the small bowel from which it was obtained. This may not be reflective of the
bacterial contents of the entire intestine leading to false negative results (Xie, 2011). A
standardized protocol does not exist for obtaining aspirates and there is lack of clarity for
the cutoff values indicating a positive culture result. For these reasons, this method is not
an appropriate test for those with mild nonspecific symptoms or who need repeated
testing (Sieczkowska, 2016).
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Hydrogen breath testing is commonly used as an alternative method to diagnose
SBBO, however it is difficult to administer (DiBaise et al, 2006). This test is inaccurate
when pediatric patients cannot breathe into the collecting device correctly and is
ineffective for patients with respiratory distress (Malik et al., 2011). This highly
specialized testing requires specific equipment and trained technicians which are not
readily available at many institutions (Xie, 2011). Alternatives to the hydrogen breath
test include the C and D xylose breath test, which measures pulmonary excretion of
labeled CO2 produced from bacterial fermentation. Although initial reports were
promising, diagnostic specificity and sensitivity has not been confirmed (DiBaise et al.,
2006).
Molecular fingerprinting of bacterial populations is a developing area of interest
for clinical use, especially in the setting of intestinal failure and suspected SBBO.
Deoxyribonucleic acid (DNA) fingerprinting techniques can be applied to non-invasively
obtained specimens, such as fecal samples. Using universal bacterial 16S ribosomal
ribonucleic acid (RNA) primers, testing procedures produce a quantitative and qualitative
result as well as specific detection of a wide range of bacterial species. Polymerase chain
reaction (PCR) is regarded as superior over standard culture because it can detect
uncultivable or dead bacterial cells in situ; however DNA purification is required to
decrease the interference of confounding factors such as the bile salts and bilirubin found
in fecal samples making this testing method more complicated (Malik et al., 2011).
Each of the above methods have varying utility for determining the presence of
bacteria in the small bowel, but lack the ability to assess the consequences of the bacterial
presence. Small bowel biopsy specimens may provide the most useful information in
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determining if the excess bacteria in the small bowel are causing harm. Inflammation,
villus blunting, and the presence of adherent or intracellular bacteria on biopsy are
suggestive of SBBO (DiBaise et al., 2006). However, obtaining a small bowel biopsy is
also invasive and requires a sedated procedure, therefore not feasible for mild
presentations or in very ill patients. Due to the difficulty in testing for SBBO, diagnosis
is often based on the clinicians’ assessment of the risk factors as well as clinical signs and
symptoms.
Purpose Statement
The main purpose for conducting the evidence-based practice project was to
establish the role of antibiotic therapy as treatment for small bowel bacterial overgrowth
in pediatric patients with short bowel syndrome using an evidence-based approach.
There were two specific aims for this project. The first aim was to increase provider
knowledge about the risk factors for small bowel bacterial overgrowth, the signs and
symptoms consistent with small bowel bacterial overgrowth, and the preferred antibiotic
treatment options when clinically indicated. The second aim was to develop a BESt
document reflective of the recommendations derived from this project for institutional
use.
Evidence-based Practice Model
Dramatic changes in healthcare and the continued growth of integrated healthcare
delivery systems have increased the clinician’s desire to have up to date information on
effective approaches to patient care (Rosswurm & Larrabee, 1999). Clinicians can no
longer rely exclusively on clinical experience, pathophysiologic rationale, and opinionbased processes. They must also must learn to search the literature, critically appraise
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research findings, and then synthesize empirical and contextually relevant evidence. The
combination of critical thinking and evidence-based practice models for decision-making
are essential for maximizing the quality and cost-effectiveness of patient care (Rosswurm
& Larrabee, 1999).
Evidence-based practice is known as the integration of the best available research
combined with clinical expertise and patient values to promote clinical decision-making
(Melynk, 2015; Rosswurm & Larrabee, 1999). An increase in the number of clinical
research studies, particularly randomized clinical trials, meta-analysis, and patient
outcome studies has prompted the paradigm shift from traditional and intuition-driven
practice to the new standard of evidence-based practice. The use of evidence-based
practice has been established to decrease the time between conducting research and the
use of research in clinical settings.
The process of implementing evidence-based practice into patient care can be
overwhelming, complicated, and challenging. These deterrents have led to the
development of various evidence-based practice models. The use of such models support
an organized approach to implementation, improve the utility of available resources, and
facilitate the evaluation of outcomes (Gawlinski & Rutledge, 2008; Schaffer, Sandau, &
Diedrick, 2013). The implementation of evidence-based practice takes into consideration
patient preferences, availability of healthcare resources, high-quality research evidence
and clinical expertise (Melynk, 2015).
Originating in 1999, the process first named the Model for Change to EvidenceBased Practice has since evolved and was updated in 2009. It is now known as the
Model for Evidence-Based Practice Change, rearranging the words to emphasize the type
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of change that results from following the model (Larabee, 2009). The Model for
Evidence-Based Practice Change was used as a guiding framework for the project
(Larabee, 2009). The model is a six step process and is further described herein (Figure
1. Adaptation of Model for Evidence-Based Practice Change)
Step 1: Assess the need for change. A clinician’s interest in a practice change may
stem from an awareness of patient or staff preferences or dissatisfaction, quality
improvement data, practitioner queries, evaluation data, or new research data (Rosswurm
& Larrabee, 1999). During this phase, the clinician will identify the practice problem and
notify key stakeholders, collect internal data, compare internal data to external data to
confirm the need for a practice change, then link the problem, interventions and outcomes
in a meaningful way (Larabee, 2009). It is key during this phase to secure buy-in from
key stakeholders to maximize likelihood of success. Step two: Locate the best evidence.
The clinician plans and conducts a literature search using key words from the clinical
problem, intervention, and desired outcome. During this step, the clinician uses a table of
evidence or matrix for organizing data about the research studies. Step three: Critically
analyze the evidence. In the critical appraisal of the literature, clinicians evaluate the
strengths and weaknesses of studies and identify gaps and conflicts in the literature
(Rosswurm & Larrabee, 1999). Step four. Design practice change. In the design phase,
the clinician defines the proposed change, identifies the needed resources, and then
designs the implementation and evaluation process (Larabee, 2009). A proposed change
may be in the format of a protocol, procedure, or standard. Step five. Implement and
evaluate change in practice. Actual implementation of the proposed change occurs in
this step, but may be limited to a select number of patients if the clinician is part of a
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Step 1: Assess need for practice change
-

Step 2: Locate the best evidence

Inconsistencies have been
identified in the diagnosis and
treatment of pediatric patients with
short bowel syndrome and SBBO

-

Step 6: Integrate & maintain practice
change
-

Develop PICOT question
Search Cochrane, CINAHL, and
PubMed databases
Identify keeper articles

Step 3: Critically analyze the evidence
-

Implement clinical practice guide
into standard practice within the
division at project institution
Disseminate results to division
through electronic communication
and faculty meetings

Diagnosis of SBBO in pediatrics is
difficult due to complex testing
methods
Diagnosis is often made based on
risk factors and clinical symptoms
Interventional studies in pediatrics
are limited
Treatment is based on clinical
experience and favors antibiotic
use

-

Step 5: Implement & evaluate
practice change
-

Step 4: Design practice change
-

Develop clinical resource for
identification & treatment of SBBO
Educate clinical staff
Evaluate use of clinical resource as
a guide for identification &
treatment of SBBO

Create an EBP project proposal
Create an EBP project timeline
Assess current clinical practices
through retrospective chart
review

Figure 1. Adaptation of Model for Evidence-Based Practice Change. (Larabee, 2009)

15

larger organization. Following the implementation, an evaluation of the process,
outcomes, and costs is conducted. Based on evaluation results, conclusions and
recommendations can be made (Larabee, 2009). Step six. Integrate and maintain change
in practice. If the evaluation outcomes are favorable, steps are made to integrate the
change into practice. Recommended changes are communicated to the key stakeholders,
the new process is integrated into a standard of care, and evaluation of outcomes
continue. Finally, dissemination of the project outcomes and recommendations to a
wider audience such as in a peer reviewed publication is recommended.
The Model for Evidence-Based Practice Change is a progressive, but not a linear
process. The bi-directional arrows between two steps indicate that activities in each step
may stimulate activities in the other step (Larabee, 2009). Following the steps of an
evidence based model of change can lead to successful implementation and sustainment.
Cincinnati Children’s Hospital Medical Center (CCHMC) endorses the use of evidencebased decision making as a way to achieve the best and safest care for patients. Patients
and families expect clinical practice to be based on knowledge from current research in
the field. To support clinicians at CCHMC, the James M. Anderson Center for Health
Systems Excellence was created to promote, guide, and support improvement work and
health services research. They also strive to spread the impact of such work into clinical
practice and policy. The Evidence-Based Decision Making (EBDM) process was created
at CCHMC to integrate the best research or clinical evidence available with the clinical
expertise and patient and family values to facilitate clinical decision making (CCHMC,
2017).
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The Evidence-Based Decision Making (EBDM) process consists of five steps and
parallels the process established in the Model for Evidence-Based Practice Change. Step
one is the development of a clinical question in PICOT format. PICOT is an acronym for
the five components of a clinical question including population, intervention,
comparison, outcome, and timeframe. The clinical question is arguably the most
important step in the process as a well-worded question is likely to yield the most
relevant literature search results.
Following the development of a PICOT formatted clinical question, a literature
search is conducted using key components of the clinical question. Once the literature
search is completed, the critical appraisal process begins. In step four, all relevant
research is then summarized and consolidated into a synthesis table with an associated
level and grade for each piece of evidence as well as a statement judging the strength of
recommendations for practice change. The final step of the EBDM process is the
development of a care recommendation. Care recommendations are based on the body of
evidence available and other components for judging the strength of a recommendation.
At CCHMC, evidence-based care recommendations may be presented as a BESt (Best
Evidence Statement) or as Evidence-Based Care Guidelines (EBCG). A BESt is shorter
than an EBCG and contains clinical recommendations on a limited topic or single clinical
question. EBCG aim to answer multiple health or clinical questions regarding disease
management and are designed to meet criteria for quality in the development of evidencebased care recommendation statements from the National Guideline Clearinghouse and
Appraisal of Guidelines for Research and Evaluation. After an evaluation of the
literature, review of current practices at CCHMC and collaboration with division leaders,
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recommendations were prepared using BESt guidelines. Preparation of the BESt
document was guided by the CCHMC BESt Development Manual. The manual is
available for public viewing and can be accessed at
https://www.cincinnatichildrens.org/service/j/anderson-center/evidence-basedcare/legend.
Following the Model for Evidence-Based Practice Change, a clinical problem was
identified and the need for practice change was established. Key stakeholders were
identified and supported the project. The clinical problem was addressed using the
interventions that will be described in the implementation section. Planning and
conducting a thorough literature search was the next step in the process and described
herein. Using the PICOT format, a clinical question was formulated to guide the
literature search.
PICOT Question
The PICOT question used to guide the literature search for this project was: “In
pediatric patients with short bowel syndrome presenting with signs and symptoms of
SBBO, how does treatment with antibiotics compared to no treatment affect the
symptoms of abdominal distention, vomiting and increased stool output?” To further
clarify the PICOT question, pediatric patients in this setting is defined as patients aged
newborn through 18 years. The signs and symptoms of SBBO are aligned with those
listed above in the signs and symptoms section.
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II.

EVIDENCE

A literature search was conducted using key components of the PICOT question
to find the best available evidence. The search was conducted using Cochrane Database
for Systematic Reviews, CINAHL and PubMed databases. Keywords used and
limitations applied are outlined in Appendix A. Pediatric research in this field is limited,
so the search was not restricted to only pediatric populations. Additional articles were
identified by hand searching the reference lists of reviewed articles. Multiple articles
were reviewed, 13 met the inclusion criteria for the project based on the PICOT question.
Additional articles that provided information relevant to the clinical question in adult
populations were used to support the findings in pediatric literature. Background
information was provided by articles not otherwise relevant to the clinical question, these
were not critically appraised.
Critical appraisal
Once the literature search was complete, the critical appraisal process began. The
CCHMC Evidence Collaboration has developed and adapted tools for evaluating
evidence known as the ‘Let Evidence Guide Every New Decision’ (LEGEND) system.
Developed at CCHMC, the LEGEND system consists of six tools including a glossary of
terms, table of evidence levels, algorithm to determine the study design, evidence
appraisal forms, algorithm to grade the body of evidence, and templates regarding
judging the strength of a recommendation (Clark, Burkett, & Stanko-Lopp, 2009).
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The LEGEND system was selected for the critical appraisal of the literature.
Each study is given a numeric value (1-5) based on the study design. Number one
represents the highest quality of research available such as a systematic review or metaanalysis and number five represents lesser quality evidence such as expert opinion.
Appendix B, Table of Evidence Levels, displays criteria for leveling research evidence.
After determining the design of each study, LEGEND evidence appraisal forms were
used to determine the quality level. The evidence appraisal forms guide users through
questions of validity, reliability and applicability to the clinical question. LEGEND
appraisal forms are specific to the study design and domain of the clinical question (Clark
et al., 2009). The quality of a study refers to the extent to which all aspects of the study
design and conduct establish protection against bias. Quality level “a” indicates good
quality evidence and level “b” indicates lesser quality. A quality level of not valid,
reliable or applicable is an option for literature that does not answer the question of
interest. Appendix C, LEGEND critical appraisal forms, provides examples used for
appraisal of expert opinion and systematic reviews.
After leveling each individual study, the next step is grading the body of
evidence. This allows for consideration of the quality, quantity, and consistency of the
body of evidence. The quality of the body of evidence is assigned a grade of high,
moderate, low or grade not assigned. High grade indicates a sufficient number of high
quality studies with consistent results. Moderate grade indicates either multiple studies
of lesser quality or with inconsistent results or a single well-done study. Low grade
refers to body of evidence consisting mostly of expert opinion, case reports, case studies
and general reviews. Grade not assigned is used when all of the studies are of
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insufficient design or execution, too few studies, or inconsistent results within the body
of evidence (Clark et al., 2009). Appendix D, Grading the Body of Evidence forms, was
used for grading the quality of the body of evidence.
Evidence was then summarized and consolidated into a synthesis table. Judging
the strength of each practice recommendation was completed using the LEGEND system.
Judging the strength of a recommendation consists of six dimensions including: grade the
body of evidence, degree of harm to the patient, benefit to targeted population, burden on
population to adhere to recommendation, cost-effectiveness to healthcare system,
directness to the extent to which the body of evidence directly answers the clinical
question and impact on morbidity, mortality, and quality of life. The options for judging
the strength of a recommendation using the LEGEND system are ‘strong
recommendation’, ‘recommendation’, and ‘unable to make a recommendation’ (Clark et
al., 2009). Appendix E Judging the Strength of a Recommendation form was used to
judge the overall strength of practice recommendations.
The literature review focused on answering the clinical question about the
effectiveness of antibiotic therapy to treat symptoms of SBBO in pediatric patients with
short bowel syndrome. Most of the supportive evidence came from expert opinion and
review articles because randomized controlled trials investigating antimicrobial therapy
to treat SBBO in pediatric patients with short bowel syndrome are scarce. A summary of
the pediatric literature can be found in Appendix F. Clinicians often diagnose SBBO
based on risk factors in combination with clinical presentation then recommend treatment
with empiric antibiotics. Goals of treatment should focus on correction of the underlying
disease or structural defect, elimination of predisposing conditions, nutritional
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replenishment and modification of the gastrointestinal microbiota by reducing or
eliminating sluggish bowel motility and cleansing the bowel of pathogenic bacteria
(Sieczkowska et al., 2016; Vanderhoof et al., 1998).
Due to the lack of randomized clinical trials in children, there is not a specific
approved therapy for small bowel bacterial overgrowth. However, a variety of empiric
antibiotics are used. Appendix G contains a summary of commonly recommended
antibiotic and non-antibiotic treatment options in pediatric patients. Because there
currently are no controlled trials studying the treatment of SBBO in pediatric patients
with short bowel syndrome, recommendations are made on the basis of clinical
experience.
The most commonly recommended antibiotic choices include metronidazole,
rifaximin, sulfamethoxazole/trimethoprim, and amoxicillin/clavulanic acid.
Metronidazole is an absorbable antimicrobial agent and the most popular agent for
eradicating anaerobes in this setting (Cole & Kocoshis, 2013). Rifaximin, a nonabsorbable antimicrobial, also covers obligate anaerobes effectively and is frequently
used. Lack of insurance coverage and high costs make the use of rifaximin prohibitive
for many patients. Putrefactive, gram-negative aerobes may be treated with
sulfamethoxazole-trimethoprim, oral gentamycin, extended-spectrum penicillin or
cephalosporin therapy (Cole & Kocoshis, 2013). Less common antibiotic choices include
tobramycin, Colistin, chloramphenicol, clindamycin and vancomycin.
Mirroring the findings in pediatric literature, metronidazole and rifaximin were
the most commonly studied and recommended antibiotic choices to treat symptoms of
SBBO in adults. Summary and synthesis of the adult literature can be found in
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Appendices H and I. Di Stefano et al. (2005) studied the efficacy of metronidazole
verses rifaximin in a group of adult patients with documented SBBO and short bowel
syndrome. The metronidazole group was prescribed 250 mg twice daily and the
rifaximin group was prescribed 400 mg three times daily, each for a 7-day period. While
both antibiotics were effective, they found that metronidazole was more effective than
rifaximin in reducing hydrogen breath excretion and gastrointestinal symptoms.
In a separate study by Lauritano et al. (2005), they examined the effectiveness of
different doses of rifaximin in adult patients with positive breath tests and other
predisposing conditions that result in symptoms of bloating, abdominal discomfort and
diarrhea. They found that a 1200 mg daily dose was associated with significantly higher
therapeutic efficacy in eradication of symptoms than lower daily doses. Lauritano et al.
(2009) later studied the effectiveness of rifaximin 1200 mg daily versus metronidazole
750 mg daily in patients with irritable bowel syndrome and symptoms of SBBO. They
found that rifaximin was associated with a higher decontamination rate based on pre and
post breath tests (Lauritano et al., 2009). The difference in efficacy of rifaximin between
the three studies may be explained by the absence of short bowel syndrome in the latter
two. In order for rifaximin to be most efficient it must reach the site of bacterial
overgrowth and achieve local concentration, suggesting that in short bowel syndrome
these conditions may not be adequately satisfied making rifaximin less effective when
compared to metronidazole in that population (Di Stefano et al., 2005).
Attar et al. (1999) studied the effectiveness of norfloxacin, amoxicillin-clavulanic
acid, and a probiotic in treating symptoms associated with SBBO. Patients underwent
five 7-day treatment periods including an untreated control period, placebo period, then

23

in random blinded fashion underwent a course of norfloxacin, amoxicillin-clavulanic
acid, and Saccharomyces boulardii. Results showed norfloxacin and amoxicillinclavulanic acid to be effective in treating overgrowth related diarrhea. Although this
study was limited by excluding pediatric patients, it provided useful information
regarding symptom improvement on specific antibiotics and should be considered when
making recommendations.
Based on the LEGEND criteria for grading a body of evidence, the combined
pediatric and adult evidence receives a moderate grading. A moderately graded body of
evidence contains multiple studies with varying strength of design and have relatively
consistent results with minor exceptions. Most of the supportive evidence comes from
pediatric expert opinions or review articles, however included in this body of evidence is
at least one systematic review and several adult cohort studies.
Non-antibiotic recommendations include flushing the bowel with polyethylene
glycol 3350, dietary modification, glutamine, probiotics, prokinetic agents, and surgical
correction of underlying anatomic abnormalities (Ching et al., 2007; Cole & Ziegler,
2007; Dehmer et al., 2011; DiBaise et al., 2006; Malik et al., 2011; Quigley & Quera,
2006; Reed, 2014; Sentongo, 2008; Shah et al., 2013; Sieczkowska et al., 2016;
Vanderhoof et al., 2003; Youssef et al., 2012). Polyethylene glycol 3350 is a powder
laxative commonly used to treat constipation. After mixing per manufacturer
recommendations, polyethylene glycol 3350 uses an osmotic effect to increase the
amount of water in stool making it easy to pass. Daily to weekly bowel flushes with
polyethylene glycol 3350 have been proposed to reduce bacterial counts by removing
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bacteria embedded in the mucosal lining (Reed, 2014). Published studies assessing the
effectiveness of polyethylene glycol 3350 for the use of treating SBBO were not found.
Correction of micronutrient deficiencies and diet modification are valuable
components of SBBO management. Because most bacteria ferment carbohydrates,
restriction of refined carbohydrates, such as concentrated sweets may aid in reducing
osmotic diarrhea in this population. Because many children with SBBO may have a
reduction in the enzyme lactase related to the mucosal injury caused by the bacteria,
avoiding lactose may help alleviate gastrointestinal discomfort. Avoiding non-absorbable
sugar alcohols, such as sorbitol and xylitol, may improve symptoms of flatulence and
abdominal distention. Due to the many restrictions, patients often benefit from a low
carbohydrate, high fat diet for optimal control of symptoms (Reed, 2014).
Glutamine is a nonessential amino acid and the primary source of energy for the
enterocyte, the cell of the intestinal lining. Glutamine has been shown to prevent
mucosal atrophy and deterioration in gut permeability in animal models and in adults
who are receiving parenteral nutrition. In adults, glutamine has been shown to improve
the growth and function of the human gut epithelial cells when used in combination with
human growth hormone and a high-fiber, low-fat diet. Data in children is inconclusive at
this time and requires additional studies to ensure efficacy and safety (Dehmer et al.,
2011).
Probiotics are defined as live microorganisms that provide health benefits to the
host when ingested. Many varieties are available, but few have undergone adequate
testing in pediatric clinical trials. The use of probiotics for treatment for SBBO is based
on the premise that the probiotic will compete with pathogenic bacteria, prevent bacterial
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translocation, and enhance mucosal barrier (Reed, 2014). The risk to benefit ratio of
probiotics, especially in children with immature immune systems and indwelling central
venous catheters, have been debated in medical literature. Septic episodes due to
probiotic organisms have been documented leading to avoidance of probiotics in
pediatric patients with central venous catheters (Malik et al., 2011; Youssef et al., 2012).
For patients with short bowel syndrome and an intact colon, the use of probiotics that
produce D-lactate increase the risk of developing the life-threatening condition, D-lactic
acidosis (DiBaise et al., 2006; Youssef et al., 2012).
Prokinetic therapy has been suggested to increase the motility of the bowel
thereby decreasing stasis and potential for bacterial overgrowth. Prokinetic agents such
as metoclopramide, erythromycin, and cisapride have been shown to promote motility in
these patients but their use is restricted due to potentially harmful side effects.
Metoclopramide is a central and peripheral dopamine type 2 receptor antagonist that has
a variety of central nervous system side effects including dystonic reactions,
extrapyramidal side effects, and tardive dyskinesia (Ching et al., 2007).
Erythromycin has been used as a motilin receptor agonist and is associated with
various drug interactions. Cisapride, a 5-HT3 agonist, is associated with serious cardiac
arrhythmias and sudden death. Since 2000, cisapride has been part of an FDA-mandated
limited-access protocol due to concerns of serious adverse cardiac events and can only be
prescribed by providers who met strict criteria (Ching et al., 2007).
Finally, surgical correction of an underlying anatomic anomaly has been
suggested as treatment for SBBO. Surgery is normally considered when severe
symptoms recur despite adequate medical therapies. Surgical correction of anatomic
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anomalies leading to stasis and proliferation of bacteria can be immediately corrective for
SBBO symptoms (Sentongo, 2008).
Regardless of the measures used, many therapies either pose risk for
complications or become ineffective with time. Current antibiotic treatments are based
on scientific theory which favor gram negative and anaerobic antibiotics. Antibiotics are
chosen based on the bacteria presumed to cause the symptoms and based on clinical
experience. The most commonly studied and recommended antibiotics in pediatrics and
adult literature are metronidazole and rifaximin.
Clinical Knowledge Gaps
Despite the availability of clinical expert opinions and descriptive studies
regarding the use of antibiotic therapy for the treatment of SBBO, there remains a large
gap in pediatric clinical trials. A number of the pediatric expert opinions, adult
interventional studies and adult expert opinions discuss medications not commonly
prescribed in current management of clinical SBBO; however, those medications studied
did result in significant improvement in clinical symptoms correlated by improvement in
diagnostic testing results (Attar et al., 1999; Di Stefano et al., 2005; Lauritano et al.,
2005; Lauritano et al., 2009). Pediatric clinical trials are needed to fully understand the
role of antibiotics as a means to treat symptoms caused by SBBO.
Statement of Recommendations
After a thorough review and critical appraisal of the literature, recommendations
for practice were developed. Consistent with the LEGEND system, the strength of each
recommendation was evaluated using the Judging the Strength of a Recommendation
tool. It was strongly recommended that providers properly identify risk factors for
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SBBO. Learning to identify risk factors has the potential for significant benefit to this
population in terms of morbidity, mortality and quality of life. The evidence presented to
support this recommendation is largely based on expert opinion, clinical experience, and
literature review, as well as the limited pediatric research available (Bohm et al., 2013b;
L. Chan, Parrish, & DiBaise, 2015; Ching et al., 2007; Cole & Ziegler, 2007; Collins &
Lin, 2011; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et al., 2006; Gutierrez et
al., 2012; Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014;
Vanderhoof et al., 2003). Knowing the risk factors for SBBO, has the potential to
minimize overprescribing of unnecessary antibiotics. Overprescribing leads to increased
healthcare expenses while failure to comply with antibiotic stewardship increases risk of
multi-resistant organisms.
Second, it was strongly recommended that providers receive educational training
in the identification of the signs and symptoms of SBBO (Bohm et al., 2013b; L. Chan et
al., 2015; Ching et al., 2007; Cole & Ziegler, 2007; Collins & Lin, 2011; Dehmer et al.,
2011; Di Stefano et al., 2005; DiBaise et al., 2006; Gutierrez et al., 2012; Lauritano et al.,
2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014; Vanderhoof et al., 2003).
Identifying the signs and symptoms of SBBO also has the potential to have great impact
on the quality of life for those affected. Differentiating the signs and symptoms of SBBO
from other etiologies will allow providers to more quickly recognize when an antibiotic
therapy is indicated and when it is not.
Finally, it is recommended that providers receive educational training in the
identification of suitable antibiotics and doses for the treatment of SBBO (Attar et al.,
1999; Bohm et al., 2013b; L. Chan et al., 2015; Ching et al., 2007; Cole & Kocoshis,
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2013; Cole & Ziegler, 2007; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et al.,
2006; Lauritano et al., 2005; Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera,
2006; Reed, 2014; Sentongo, 2008; Shah et al., 2013; Sieczkowska et al., 2016;
Vanderhoof et al., 1998; Vanderhoof et al., 2003; Youssef et al., 2012). This
recommendation was given a strong recommendation. Based on the multitude of clinical
experiences, expert opinion, and the limited number of interventional studies available,
there is a support for a handful of specific antibiotics which have been shown to be
effective in minimizing symptoms. Appendix J Completed Judging the Strength of a
Recommendation form, provides an overview of the strength of the three practice
recommendations. After completing a review of current practices, a finalized list of
preferred antibiotics has been generated with the assistance of the collaborating
stakeholders. The preferred antibiotic list will be become part of the BESt document
used by providers caring for patients with suspected SBBO.
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III.

IMPLEMENTATION

Project Setting and Population
Cincinnati Children’s Hospital Medical Center (CCHMC) was the setting for the
project. It is one of the oldest and most distinguished pediatric hospitals in the United
States with more than 600 registered beds. Support for the project was obtained by the
Clinical Director of the Division of Gastroenterology, Hepatology, and Nutrition and
agency approval granted by the Vice President of Patient Services (Agency approval
form, Appendix K). CCHMC is second best pediatric hospital in the nation according to
the 2018-2019 U.S. News and World Report. Among those standings, Gastroenterology
ranked number three as a result of their dedication and ability to provide comprehensive
care to children with all levels of need (CCHMC, 2018).
Within the Division of Gastroenterology, Hepatology and Nutrition, the Intestinal
Care Center (ICC) exists to provide consultation, management, and long-term follow up
for children with enteral feeding tube dependence, central venous catheters with
parenteral nutrition requirements, intestinal failure and short bowel syndrome. Despite
the clear dedication to improving health outcomes for children, the ICC has not
developed a resource to assist providers in the identification and treatment of SBBO in
pediatric patients with short bowel syndrome.
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The population of interest included pediatric patients (age newborn -18 years old)
with a diagnosis of short bowel syndrome secondary to omphalocele, gastroschisis,
duodenal atresia, jejunal atresia, ileal atresia, necrotizing enterocolitis, malrotation with
volvulus, Hirschsprung’s disease or traumatic bowel injury who received treatment at
CCHMC on the inpatient Gastroenterology Lumen service between 5/1/2016-5/1/2017.
All patients who met the inclusion criteria were considered. Patients who did not meet
inclusion criteria were not included.
Most patients admitted to the Gastroenterology Lumen service are housed on
A4S, a 24-bed unit specializing in the complex care of gastrointestinal and surgical
patients. Patients admitted to the inpatient Gastroenterology Lumen service are managed
by Nurse Practitioners and second year resident physicians with oversight by a first-year
Gastroenterology fellow physician and an attending physician. The ICC followed more
than 200 patients who had the potential to be admitted during the project timeframe.
IRB determination and HIPAA compliance
Appropriate regulatory approval was required from both CCHMC and Wright
State University (WSU) to conduct a retrospective chart review. The IRB at CCHMC
must review all research involving human participants as defined by CCHMC policy in
accordance with federal regulations, applicable state laws and institutional policy.
Application for IRB determination at CCHMC was submitted through the institutions’ ePAS website. All named project participants completed Collaborative Institutional
Training Initiative (CITI) training and conflict of interest statements in accordance with
IRB determination. Approval from WSU for retrospective chart review was requested
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using their regulatory process. Determination from CCHMC and WSU IRBs was
received in summer 2017 (Appendix L and M).
Every effort was made to maintain HIPAA (Health Insurance Portability and
Accountability Act) compliance and protect patient privacy throughout the project. The
DNP student and Information Services personnel were the only individuals with access to
the patient names linked with protected patient information. Protected patient
information included patient name, electronic health record number, gender, age, date of
admission, diagnosis, presence of enteral feeding tubes or central venous catheters,
presence of risk factors, clinical symptoms, means of diagnosis, treatment, and
consequences.
All data was saved using a military grade hardware encrypted flash drive. The
flash drive was utilized to store project data. Data on the flash drive was separated into
two files. The first file was the initial report provided by the Department of Information
Services displaying patient name, electronic health record number, diagnosis and date of
admission. The second file was converted to include a randomized identifier and the
remainder of the data collection results. Each file was protected by its’ own unique
password. Only the DNP student had access to the password of the first file that included
patient identifiers. When not in use, the flash drive was kept in a locked filing cabinet in
the DNP student’s office. In the event that data had to be sent via electronic mail, the
message was sent from the DNP student’s CCHMC Outlook server and encrypted using
the prefix ‘zix:’ in the subject line of the message, which ensured encryption. All project
findings were reported in aggregate.
Implementation plan
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A one year retrospective chart review of qualifying pediatric patients on the
Gastroenterology Lumen service was planned to establish the role of antibiotic therapy as
treatment for small bowel bacterial overgrowth in pediatric patients with short bowel
syndrome using an evidence-based approach. There were two specific aims for this
project. The first aim was to increase provider knowledge about the risk factors for small
bowel bacterial overgrowth, the signs and symptoms consistent with small bowel
bacterial overgrowth, and the preferred antibiotic treatment options when clinically
indicated. The second aim was to develop a BESt document reflective of the
recommendations derived from this project for institutional use.
Identification of resources
The project team consisted of a project chair, project lead, a gastroenterology
physician, infectious disease physicians, a statistician, a pharmacist, an evidence-based
practice mentor, and support personnel. Table 1 summarizes the project team, their role
and their home agency. The DNP student served as the project lead and assumed the
majority of the project related responsibilities as well as provided oversight of the tasks
assigned to other team members. The project lead provided the conceptual design for the
project, conducted and summarized a review of the literature, secured necessary
regulatory determinations from the Institutional Review Boards (IRB) at CCHMC and
WSU, determined the data search parameters, designed the data collection tool,
performed chart review and data collection, reviewed results with project team, and
drafted the proposal for the BESt document prior to submission.
The gastroenterology and infectious disease physicians provided content
expertise, reviewed current practices as discovered through chart review and provided
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Table 1.
Project team
Name
Christie Heinzman

Role
Project Lead/DNP Student

Agency
Wright State University

Tracy Brewer

Project Chair/DNP Mentor

Wright State University

Conrad Cole

Gastroenterology Physician

Cincinnati Children’s
Hospital Medical Center

Heidi Anderson

Antibiotic Stewardship Physician

Cincinnati Children’s
Hospital Medical Center

David Haslam

Antibiotic Stewardship Physician

Cincinnati Children’s
Hospital Medical Center

Josh Courter

Antibiotic Stewardship Pharmacist Cincinnati Children’s
Hospital Medical Center

Emily Acker

Staff Pharmacist

Cincinnati Children’s
Hospital Medical Center

Mike Bottomley

Senior Statistical Consultant

Wright State University

Mary Ellen Meier

EBP/BESt Mentor

Cincinnati Children’s
Hospital Medical Center

assistance in drafting the BESt proposal document. The statistician reviewed all data and
provided assistance with data analysis. The pharmacist provided expertise in pediatric
appropriate dosing for off-label use of medications and reviewed the proposed BESt draft
document. Support personnel were enlisted to generate an electronic medical record
(EMR) report based on search parameters provided by the project lead. The evidencebased practice mentor provided guidance and support throughout the duration of the
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project. The project chair, Dr. Tracy Brewer, provided the DNP student with oversight,
counsel, and support during the implementation and evaluation phases of the project.
Project implementation
The project concept, design and review of literature was presented during the
proposal phase. The remainder of the project was completed in several phases. After
IRB determination, the Department of Information Services at CCHMC was asked to
perform a query report of the EMR system for patient admissions between 5/1/20165/1/2017 with a diagnosis of short bowel syndrome, omphalocele, gastroschisis, duodenal
atresia, jejunal atresia, ileal atresia, necrotizing enterocolitis, malrotation with volvulus,
and intestinal pseudo-obstruction using ICD-10 diagnosis codes. The report was
provided to the project lead and used to guide the chart review. A data collection tool
was used to collect data during chart review (Appendix N).
The data collection tool consisted of five sections including demographics, risk
identification, diagnostic measures, treatment measures, and sequelae. The demographic
section included patient gender, age, admission date, discharge date and survival status at
three months post admission and at the completion of the review period. The risk
identification section tracked the diagnosis and underlying condition, co-morbid
conditions, presence of a central venous catheter, route of enteral feeds, presence of risk
factors for SBBO, and presence of signs and symptoms of SBBO.
Assessment of risk factors and signs and symptoms was based on the conditions
presented in the literature synthesis table (Appendix O). Diagnostic measures assessed
the method of diagnosing SBBO including hydrogen breath testing, duodenal aspirate,
small bowel biopsy, or clinical suspicion. Assessment of treatment tracked if an
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antibiotic was prescribed with the intent to treat SBBO, which antibiotic was prescribed
and its dosing regimen, as well as the costs for the treatment course. Sequelae of interest
included resolution of symptoms and occurrence of central line associated-blood stream
infection (CLA-BSI) within three months of antibiotic course. If there was a subsequent
CLA-BSI, the organism was tracked as well as the antibiotic used to treat the preceding
SBBO, the need for central venous catheter removal and its associated length of
hospitalization.
The chart review data was then reviewed and analyzed in collaboration with the
statistical team at WSU. The detailed data analysis was discussed with the physician
mentors. The antibiotic stewardship team was brought in to review the analysis and
provide expert opinion. Following that discussion, recommendations for the BESt
document were finalized.
A BESt document has been drafted by the project lead with contributions from
key stakeholders and will be submitted to the BESt for Evidence Collaboration Review
committee by August 15, 2018 (Appendix P). Approval is anticipated to take up to 120
days from submission, approximately five months following the project defense. Project
timeline can be found in Appendix Q. The project lead is currently developing education
materials to be distributed to the clinical staff including Registered Nurses (RN),
Advance Practice Registered Nurses (APRN), resident, fellow and attending physicians.
Education materials will be finalized within 30 days following the final approval of the
BESt document by the review committee. Materials will include slide show
presentations that discuss the risk factors for SBBO, signs and symptoms of SBBO, as
well as a reference guide for treatment of SBBO.
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After the approval of the BESt document, education materials will be distributed
to clinical staff including RNs, APRNs, as well as resident, fellow and attending
physicians. Following the dissemination of educational materials, the bedside RN will be
asked to monitor the patients’ clinical status and document symptoms consistent with
SBBO. The APRN, resident, fellow and attending physicians will assess patients for
presence of SBBO and initiate treatment if indicated according to the BESt
recommendations. Additionally, providers will assess the need for continued SBBO
treatment in patients who are admitted on a prophylactic cycle of antibiotics. Physicians
and APRNs will ensure proper clinical documentation of symptoms and response to
treatment, management of EMR clinical problem list, and ensure correct diagnosis coding
for chief and comorbid conditions. Finally, dissemination of the project including a
summary of the evidence, summary of clinical practice habits during the timeframe
reviewed, and education materials will be disseminated to the entire division within 60
days following final acceptance of the BESt proposal.
Stakeholders and facilitators to implementation
The success of a clinical endeavor of such magnitude was highly dependent on
the support of the system, especially from those who are dedicated to the implementation
of the project. CCHMC’s organizational commitment to safety and quality improvement
contributed to success of this project. When considering members for inclusion into the
interdisciplinary project team, recruitment was focused on those who are passionate about
the patient population, outcome measures, cost reduction, and evidence-based practices.
Success of the project was dependent on the support and cooperation of all stakeholders
and team members.
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Barriers to implementation
Major barriers to implementation were not expected but did arise as the project
developed. Receiving determination from either IRB was not an initial anticipated
barrier. However due to staffing issues at WSU, IRB determination was delayed by more
than three months which significantly delayed the progress of the project. The intent was
to have the BESt document finalized and published by the defense of this evidence-based
project. Due to the time constraints of the WSU IRB, there was an unexpected delay and
only the retrospective chart review, data analysis, and draft development of the BESt
could be completed by the final defense.
Evaluation
Data was collected using a data collection tool (Appendix N). The data collection
tool was developed in Excel by the project lead. Excel spreadsheets can be used for
collecting and summarizing raw data (Microsoft, 2018). Data was summarized and
analyzed in collaboration with a statistical consultant at WSU. An alpha=0.05 was
selected to determine the level of significance during the analysis. SAS version 9.4
software was used for all analyses.
Outcome measures
Data was collected by retrospective chart review for specific demographic variables
and to determine outcomes for nine specific project questions important in developing the
BESt document. Method for statistical analysis was determined after consultation with
the Statistical Consulting Center at WSU.
1. Does the use of an antibiotic for presumed SBBO lead to more CLA-BSI? To
answer this question, a mixed effects logistic regression was done. The
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prevalence of CLA-BSI within three months among children who had and did not
have antibiotic treatment for SBBO was reviewed as well.
2. Do specific symptoms of SBBO lead to antibiotic treatment more often than
others? A mixed effects logistic regression was performed to answer this
question.
3. Is there a relationship between the presence of CLA-BSI and the patient’s age?
Mixed effects logistic regression was performed to answer this question.
4. Are there differences in the number of symptoms between patients who are
treated with antibiotics for SBBO and those who are not? A mixed effects
negative binomial regression was performed to answer this question.
5. Do patients being treated with antibiotics for SBBO have a shorter length of stay
than those who are not receiving antibiotics? A shared frailty Cox proportional
hazards model was performed to answer this question.
6. Do patients being treated with antibiotics for SBBO have a higher rate of
resolution of symptoms than those who are not receiving antibiotics? A simple
count for the visits with known resolutions of symptoms was performed to answer
this question.
7. How many of the reviewed patients (in terms of visits) were prescribed antibiotics
who did not meet the criteria for risk factors for SBBO or have signs/symptoms of
SBBO? Of these, how many antibiotics exposed days were there? What was the
costs of the antibiotics? Descriptive analysis was used to answer these questions.
8. Of the reviewed patients (in terms of visits) who received antibiotic treatment for
SBBO, how many developed a CLA-BSI within three months? What SBBO
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antibiotic was used? What organism/s grew? Did the central venous catheter
have to be removed? If the line was removed, how many additional days did the
patient stay in the hospital? Descriptive statistics were used to answer these
questions.
9. Do patients with certain anatomic risk factors who are treated with antibiotics for
SBBO have CLA-BSI more frequently than patients with other anatomic risk
factors? A mixed effects logistic regression was used to answer this question.
Table 2 provides an explanation of specific outcome measures, variable codes and
associated data collection methods.
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Table 2.
Explanation of data variables
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Topic

Measure

Code

Variable

Collection method

DEMO1

Patient ID number

PT ID

Numeric

Assigned

DEMO2

Gender

DGEN

Chart review

DEMO3

Patient date of birth

DDOB

1=M
2=F
00/00/0000

DEMO4

Age at admission

DAGE

#

Chart review

DEMO5

Admit date

DADMIT

00/00/0000

Chart review

DEMO6

Discharge date

DDC

00/00/0000

Chart review

DEMO7

Length of stay

LOS

Numeric

Calculated

DEMO8

Survived at 3 months
post admission

SUR3MO

1=yes
2=no

Chart review

DEMO9

Survived at end of study

SUREND

1=yes
2=no

Chart review

RISK1

Primary diagnosis

RPDIAG

ICD-10 code

Chart review

RISK2

Secondary diagnosis

RSDIAG

ICD-10 code

Chart review

RISK 3

Additional diagnosis

RSDIAG2

ICD-10 code

Chart review

Chart review
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Topic

Measure

Code

Variable

Collection method

RISK4

Additional diagnosis

RSDIAG3

ICD-10 code

Chart review

RISK5

Additional diagnosis

RSDIAG4

ICD-10 code

Chart review

RISK6

Additional diagnosis

RSDIAG5

ICD-10 code

Chart review

RISK7

Additional diagnosis

RSDIAG6

ICD-10 code

Chart review

RISK8

Presence of central venous RCVC
catheter

1=yes
2=no

Chart review

RISK9

Oral nutrition

RFEEDPO

1=yes
2=no

Chart review

RISK10

Enteral nutrition

RFEEDEN

1=yes
2=no

Chart review

RISK11

Parenteral nutrition

RFEEDIV

1=yes
2=no

Chart review

RISK12

Short bowel syndrome

ANT1

1=yes
2=no

Chart review

RISK13

Abdominal wall defect
(gastroschisis or
omphalocele)

ANT2

1=yes
2=no

Chart review
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Topic

Measure

Code

Variable

Collection method

RISK14

Small bowel atresia
(duodenal, jejunal, or
ileal)

ANT3

1=yes
2=no

Chart review

RISK15

Necrotizing enterocolitis

ANT4

1=yes
2=no

Chart review

RISK16

Malrotation with or
without volvulus

ANT5

1=yes
2=no

Chart review

RISK17

Hirschsprung’s disease

ANT6

Chart review

RISK18

Presence of an ostomy

ANT7

1=yes
2=no
1=yes
2=no

RISK19

Dysmotility

FUNC1

1=yes
2=no

Chart review

RISK20

Chronic intestinal pseudo- FUNC2
Obstruction or Megacystic
Microcolon Intestinal
Hypoperistalsis Syndrome

1=yes
2=no

Chart review

RISK21

Radiation enteropathy

FUNC3

1=yes
2=no

Chart review

RISK22

H. pylori

FUNC4

1=yes
2=no

Chart review

Chart review
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Topic

Measure

Code

Variable

Collection method

RISK23

Proton pump inhibitor use

FUNC5

1=yes
2=no

Chart review

RISK24

Hypochlorhydria

FUNC6

1=yes
2=no

Chart review

RISK25

Total or subtotal
gastrectromy

FUNC7

1=yes
2=no

Chart review

RISK26

Immunodeficiency

MULTI1

1=yes
2=no

Chart review

RISK27

Malnutrition

MULTI2

1=yes
2=no

Chart review

RISK28

Chronic pancreatitis

MULTI3

1=yes
2=no

Chart review

RISK29

Total parenteral nutrition

MULTI4

1=yes
2=no

Chart review

RISK30

Nausea/vomiting

SIGNS1

1=yes
2=no

Chart review

RISK31

Dehydration

SIGNS2

1=yes
2=no

Chart review

RISK32

Abdominal pain

SIGNS3

1=yes
2=no

Chart review
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Topic

Measure

Code

Variable

Collection method

RISK33

Distention/bloating/gas

SIGNS4

1=yes
2=no

Chart review

RISK34

Diarrhea/steatorrhea

SIGNS5

1=yes
2=no

Chart review

RISK35

Hematochezia

SIGNS6

1=yes
2=no

Chart review

RISK36

Weight loss
Malabsorption

SIGNS7

1=yes
2=no

Chart review

RISK37

Metabolic acidosis

SIGNS8

1=yes
2=no

Chart review

DIAG1

Diagnostic method

DMETH

1=Other method including
breath test, DNA PCR, duodenal
aspirate or small bowel biopsy
5=Clinical suspicion
6=Prior to admission med

Chart review

TREAT1

Treatment administered

TGIVEN

1=Yes
2=No
3=Prior to admission
medication stopped at
discharge

Chart review

Measure

Code

Variable

Collection method

TREAT2

Antibiotic prescribed

TABX

1=Amphotericin
2=Amoxicillin-Clavulanic acid
3=Cephalosporin
4=Ciprofloxacin
5=Chloramphenicol
6=Clindamycin
7=Colistin
8=Doxycycline
9=Gentamicin
10=Metronidazole
11=Neomycin
12=Norfloxacin
13=Rifaximin
14=Tetracycline
15=Tobramycin
16=Trimethoprim/sulfa
17=Vancomycin
18=Nitazoxanide

Chart review

TREAT3

Treatment dose prescribed

TREGIMEN

Descriptive

Chart review

TREAT4

Cost of antibiotic
treatment

TCOST

Number value

Inpatient pharmacy

TREAT5

Second antibiotic
prescribed

TABX2

1=Amphotericin
2=Amoxicillin-Clavulanic acid
3=Cephalosporin
4=Ciprofloxacin

Chart review
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Topic

Topic

Measure

Code

Variable

Collection method
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5=Chloramphenicol
6=Clindamycin
7=Colistin
8=Doxycycline
9=Gentamicin
10=Metronidazole
11=Neomycin
12=Norfloxacin
13=Rifaximin
14=Tetracycline
15=Tobramycin
16=Trimethoprim/sulfa
17=Vancomycin
18=Nitazoxanide
TREAT6

Treatment dose prescribed

TREGIMEN2

Descriptive

Chart review

TREAT7

Cost of antibiotic
treatment

TCOST2

Number value

Inpatient pharmacy

Measure

Code

Variable

Collection method

SEQ1

Documented resolution of
symptoms

SEQRES

1=yes
2=no

Chart review

SEQ2

CLA-BSI within three
months of treatment for
SBBO

SEQCLABSI

1=yes
2=no

Chart review

SEQ3

If SEQ2 is yes, what
antibiotic was prescribed
for SBBO

SEQCLAABX

1=Amphotericin
2=Amoxicillin-Clavulanic acid
3=Cephalosporin
4=Ciprofloxacin
5=Chloramphenicol
6=Clindamycin
7=Colistin
8=Doxycycline
9=Gentamicin
10=Metronidazole
11=Neomycin
12=Norfloxacin
13=Rifaximin
14=Tetracycline
15=Tobramycin
16=Trimethoprim/sulfa

Chart review

If SEQ2 is yes, what
organism grew

SEQCLAORG

1=Staph
2=Strep
3=Enterococcus
4=Klebsiella
5=Candida

Chart review
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Topic

SEQ4

Topic

Measure

Code

Variable

Collection method

6=Other

49

SEQ5

Second organism grown

SEQCLAORG2

1=Staph
2=Strep
3=Enterococcus
4=Klebsiella
5=Candida
6=Other

Chart review

SEQ6

If SEQ2 is yes, was
central line removed

SEQREMCVC

1=Yes
2=No

Chart review

SEQ7

If SEQ2 is yes, how long
was subsequent hospital
stay

SEQLOA

Numeric value

Chart review

IV. FINDINGS
This evidence-based project was successful in creating a new body of knowledge
related to the use of antibiotic therapy for the treatment of SBBO in pediatric patients
with short bowel syndrome. Due to limitations of the sample size, not all of the outcome
measures were able to be analyzed. During the specified timeframe of interest, 146
hospital admission visits were reviewed representing 83 unique patients. Each hospital
admission was counted as one visit. Some patients had more than one visit during the
timeframe of interest, which explains the numerical difference between visits and
patients.
Demographics
Approximately 65% of the patients were male compared to 35% female. The age
of the patients ranged from birth to 18 years of age (M = 6.94, SD = 5.11). Patient
survival at three months post admission and at the conclusion of the review period was
the same at 98.6%. This finding represents two patients that died during hospitalization.
Table 3 summarizes the demographic data.
Risk Factors
Of the 146 admission visits, a patient presented with an indwelling central venous
catheter at admission more than half of the time (n=97). This was the leading risk factor.
The most common anatomic risk factor was short bowel syndrome (n=79), followed by
presence of an ostomy, intestinal malrotation, Hirschsprung’s disease, necrotizing

50

enterocolitis, small bowel atresias and abdominal wall defects including gastroschisis and
omphalocele.
Table 3.
Demographic data
Variable
Encounters
Hospital admissions
Unique patients

Count

Frequency

146
83

Gender
Male
Female
Age in years
Mean
SD
Range
Patient survival
Alive on admission
Alive at 3 months post
admission
Alive at end of review
period

95
51

64.38%
35.62%

6.94
5.11
0-18
146

100%

144

98.6%

144

98.6%

Some patients had more than one anatomic risk factor. The most common functional risk
factor was PPI use (n=72), followed by intestinal dysmotility, then chronic intestinal
pseudo-obstruction and megacystis microcolon intestinal hypoperistalsis syndrome. The
most common multi-factorial risk factor for SBBO was TPN use (n=85), followed by
malnutrition, immune deficiency and chronic pancreatitis. Table 4 summarizes the
prevalence of risk factors.
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Table 4.
Prevalence of risk factors
Risk factor
Presence of a central line

Count (n)
97

Prevalence
66.0%

Anatomic risk factors
Short bowel syndrome

79

54.11%

Presence of an ostomy

43

29.5%

Intestinal malrotation

39

26.7%

Hirschsprung’s disease

32

21.9%

Necrotizing enterocolitis

29

19.8%

Small bowel atresias

24

16.4%

Abdominal wall defects

21

14.3%

Functional risk factors
Proton pump inhibitor use

72

49.3%

Intestinal dysmotility

70

47.9%

CIPO & MMIHS

30

20.5%

Radiation enteropathy

0

0.00%

Hypochlorhydria

0

0.00%

Prior gastrectomy

0

0.00%

Multi-factorial risk factors
TPN dependence

85

58.3%

Malnutrition

38

26.0%

Immune deficiency

6

4.10%

Chronic pancreatitis

1

0.68%
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Antibiotics
The four most commonly prescribed antibiotics for SBBO were metronidazole,
nitazoxanide, rifaximin, and sulfamethoxazole/trimethoprim. Several other antibiotics
were also used for SBBO. Non-antibiotic methods were not used. Table 5 summarizes
all of the antibiotics prescribed for SBBO during the chart review period.
Table 5.
Antibiotics prescribed for SBBO
Antibiotic
metronidazole

Count (n)
34

Prevalence
65.0%

nitazoxanide

6

11.5%

rifaximin

5

9.62%

sulfamethoxazole/trimethoprim

4

7.69%

amoxicillin-clavulanic acid

2

3.85%

vancomycin

1

1.92%

Outcome Questions
Does the use of an antibiotic for presumed SBBO lead to more CLA-BSI?
For each of the patients in the chart review, it was noted whether they had a central
venous catheter, if it became infected within three months of admission and if they were
prescribed antibiotics for SBBO. Any patient without a central venous catheter was
excluded from this portion of the analysis (n=49). Two patients were already taking an
antibiotic upon admission to the hospital and were also excluded from the analysis. Since
patients could be admitted to the hospital more than once during the given year, a random
subject effect was included to account for any correlations between admissions by the
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same patient. A mixed effects logistic regression was used for this analysis. Mixed
effects mean there are both fixed and random effects (Upton & Cook, 2014). In this case,
the fixed effect is “antibiotic use” and the random effect is a “CLA-BSI”. The mixed
effects logistic regression model yielded a p-value of 0.15, which was not sufficient to
suggest a statistically significant association between antibiotic use and CLA-BSI. Table
6 shows the relationship between antibiotic use for SBBO and resultant CLA-BSI.
Table 6.
CLA-BSI counts by antibiotic status
Use of antibiotic for SBBO

Subsequent CLA-BSI
Yes

Frequency

No

Frequency

N/Total %

Yes

7

20%

28

80%

35/100%

No

21

35%

39

65%

60/100%

Total

28

67

95/100%

Do specific symptoms of SBBO lead to antibiotic treatment more often than
others? To answer the question regarding the relationship between the presence of
specific symptoms and antibiotic prescribed upon admission, a mixed effect multiple
logistic regression was used. Again, a random subject effect was included to account for
multiple admissions by the same patient. Two patients were excluded from the analysis
since they were already taking an antibiotic upon admission (n=144). In this case, the
fixed effect is “antibiotic use” and the random effect is one of eight specific symptoms.
Variance inflation factors were checked and determined there was no multicollinearity
between the independent variables (specific patient symptoms). Multicollinearity arises
when independent variables are too strongly correlated, which results in inflated standard
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errors, which yield artificially high P-values (Upton & Cook, 2014). None of the patients
displayed symptoms of hematochezia, so no conclusions were made about that symptom.
There was not sufficient evidence to suggest that a significant association between any of
the remaining seven symptoms and antibiotic treatment, p-value > 0.19, existed. Table 7
displays individual effect of a prescribed antibiotic upon admission and specified
symptom effect.
Table 7.
Symptom effect on antibiotic treatment
Effect
Nausea vomiting
Dehydration
Abdominal Pain
Distention Bloating
Diarrhea/Steatorrhea
Weight Loss
Metabolic Acidosis

F Value
0.05
0.16
1.55
1.73
0.23
0.34
0.37

p-value
0.83
0.69
0.22
0.19
0.63
0.56
0.54

Is there a relationship between the presence of CLA-BSI and the patient’s
age? Mixed effects logistic regression was used to determine if there was a relationship
between the patients age and the presence of CLA-BSI. Again, a random effect was used
to account for multiple admissions by the same patient.
Analysis did not suggest a significant relationship between the presence of CLABSI and the patient’s age, p-value 0.65. Data was further analyzed to assess the
frequencies of CLA-BSI in patients under the age of four (n=10) and over the age of four
(n=18). There was not sufficient evidence to suggest there is a significant relationship
between a patient being under or over the age of four and CLA-BSI, p-value 0.85.
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Are there differences in the number of symptoms between patients who are
treated with antibiotics for SBBO and those who are not? Descriptive statistics,
frequencies and a mixed effects negative binomial regression was used to determine if
there was a relationship between the number of symptoms present and the use of
antibiotic treatment for SBBO. Two patients were removed from the analysis as they
were already taking antibiotics upon admission (n=144). The range of symptoms
reported was 0-5 symptoms per patient. The number of symptoms in those who received
antibiotics (M = 1.49, SD = 1.49, R = 0-5) was similar to the number of symptoms in
those who did not receive antibiotics (M = 1.22, SD = 1.37, R = 0-5). Based on a p-value
of 0.50, there is not sufficient evidence to suggest there is a significant association
between the number of symptoms and antibiotic treatment. Specific combinations of
symptoms were not tested, only the number of symptoms was considered. Table 8 shows
the relationship between the number of symptoms present and treatment for SBBO with
antibiotics.
Table 8.
Relationship between antibiotic use and number of symptoms
Use of antibiotic for
SBBO

Number of SBBO symptoms
0
1
2
3
4

5

Yes
Frequency
Row percent

15
33%

12
27%

7
16%

6
13%

1
2%

45

No
Frequency
Row percent

38
38%

30
30%

12
11
12% 11%

6
6%

2
2%

99

Total

53

42

19

12

3

56

4
9%

15

Total
patients

144

Do patients being treated with antibiotics for SBBO have a shorter length of
stay than those who are not receiving antibiotics? A shared frailty Cox proportional
hazards model was used to determine if patients who are treated with antibiotics for
SBBO have a shorter length of stay than those who do not receive antibiotics. Frailty
models are subject-specific survival models with at least one random effect that corrects
for bias in fixed effect parameter estimates and estimates of standard errors due to
unobserved correlation between observations (Amrhein, 2014). The length of stay for
patients who received antibiotics for SBBO ranged from 1-152 days (M = 18.8, SD =
36.32), while those who did not receive antibiotics stayed between 0-108 days (M = 11.6,
SD = 20.53). Data did not suggest a significant association between antibiotic use and
length of stay in the hospital, p-value 0.13. However, clinical significance is noted in that
those patients who did not receive antibiotics resulted in an average 7.2 fewer
hospitalization days.
Do patients being treated with antibiotics for SBBO have a higher rate of
resolution of symptoms than those who are not receiving antibiotics? Whether the
symptoms resolved for patients treated with antibiotics could only be established based
on the chart review, however documentation was insufficient and no statistical conclusion
could be made. Only 10 cases or four unique patients from the chart review documented
whether there was a resolution of symptoms. It was hypothesized that those who
received antibiotics would have a higher rate of symptom resolution than those who did
not receive antibiotics. Unfortunately, there was not enough data to make a statistical
conclusion to support that hypothesis. Interestingly, the data did show that those who did
not receive antibiotics actually had a shorter length of stay by 7.2 hospital days.
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However, comparison of their illnesses were not made. Actual counts of the visits with
known resolutions of symptoms based on antibiotic status is provided in Table 9.
Table 9.
Resolution of symptoms by antibiotic status
Antibiotic
Yes
No
Total

Resolution of Symptoms
Yes
4/44%
1/100%
5

No
5/56%
0
5

Total
9
1
10

How many of the reviewed patients (in terms of visits) were prescribed
antibiotics who did not meet the criteria for risk factors for SBBO or have
signs/symptoms of SBBO? Of these, how many antibiotics exposed days were there?
What was the costs of the antibiotics? Every patient reviewed had at least one
anatomical, functional, or multi-factorial risk factor. However, there were 15 visits
representing 11 unique patients who did not have documented signs or symptoms of
SBBO but were prescribed antibiotics. This represents 342 antibiotic exposed days and
more than $24,000 in medication costs. Of the 41 patient visits that were exposed to
antibiotics, most of them were a continuation of a home medication (n=27) prescribed as
a recurring medication based on prior clinical suspicion. Twelve cases were prescribed
antibiotics based on clinical suspicion during that visit. Only 2 patients underwent more
extensive testing such as duodenal aspirate during their visit.
Of the reviewed patients (in terms of visits) who received antibiotic treatment
for SBBO, how many developed a CLA-BSI within three months? What SBBO
antibiotic was used? What organism/s grew? Did the central venous catheter have
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to be removed? If the central venous catheter was removed, how many additional
days did the patient stay in the hospital? Of those who were prescribed antibiotics for
SBBO, seven admission visits representing five unique patients acquired a CLA-BSI
within three months of SBBO treatment. Metronidazole was prescribed in five of the
seven cases, Vancomycin was used once, and a combination of amoxicillin-clavulanic
acid and sulfamethoxazole/trimethoprim was used once. The most common offending
organism was a Staph species (n=6). In two of the infections, more than one organism
was isolated including one Staph species. The central venous catheter had to be removed
in six of those seven incidents. This resulted in an additional 106 hospital days with an
additional $265,000 in medical charges based on an average of $2,500 per inpatient day
for non-profit hospitals in Ohio. Table 10 summarizes CLA-BSI following antibiotic
exposure for SBBO.
Table 10.
Summary of CLA-BSI following antibiotic exposure for SBBO
Type of Antibiotic

Type of
Organism

Second
Organism

Metronidazole
Metronidazole
Metronidazole
Vancomycin
Metronidazole
Metronidazole
Amoxicillin-Clavulanic and
sulfamethoxazole/trimethoprim

Staph
Staph
Staph
Staph
Staph
Other
Staph

Other
Other
-

Central
Line
Removed
Yes
Yes
Yes
Yes
No
Yes
Yes

Additional
Days at
Hospital
19
38
18
8
6
7

Do patients with certain anatomic risk factors who are treated with
antibiotics for SBBO have CLA-BSI more frequently than patients with other
anatomic risk factors? A mixed effects multiple logistic regression was used to
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determine the relationship between the presence of certain risk factors and the incidence
of CLA-BSI. Variance inflation factors were checked and determined there was no
multicollinearity between the independent variables (anatomical risk factors). There is
strong evidence to suggest a significant relationship between “presence of an ostomy”
and developing a CLA-BSI, OR = 4.976, 95% CI [1.467, 16.879], p=0.01. This finding
suggests that patients with an ostomy have 5 times the odds of developing a CLA-BSI
then a patient without an ostomy. Findings from the analysis did not suggest a
statistically significant relationship between any of the other anatomical risk factors and
the incidence of CLA-BSI. Table 11 displays the results of the mixed effects of
anatomical factors and the presence of a CLA-BSI.
Table 11.
Anatomical factors effect on CLA-BSI
Effect
Short Bowel Syndrome
Abdominal Wall Defect
Small Bowel Atresia
Necrotizing Enterocolitis
Malrotation
Hirschsprung’s
Ostomy
*statistically significant

F-value
0.02
0.05
1.32
0.68
0.00
0.95
6.95
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p-value
0.88
0.83
0.26
0.41
0.98
0.33
0.01*

V. DISCUSSION
Literature regarding antibiotic therapy as a treatment for SBBO in pediatrics
patients with short bowel syndrome is limited. The findings highlighted in this evidencebased project were not always statistically significant. The findings are clinically
relevant and will contribute to the scientific community. The findings from this project
have paved the way for process improvement including standardization of care.
Findings from this evidence-based project were expected to determine the
effectiveness of antibiotics as a treatment in SBBO for pediatric patients with short bowel
syndrome. Unfortunately, the effect of antibiotic therapy in this population was
inconclusive due to limited clinical documentation. The data that was collected showed
that patients had symptom resolution more frequently without antibiotic therapy (n=5)
than with antibiotic therapy (n=4), but statistical conclusions could not be drawn due to
limited data. While it is noted that those who did not receive antibiotics also had a
shorter length of stay by 7.2 days, it is important to remember that patients were not
matched for illness severity and those with a longer length of stay may have had a more
complicated presentation.
As supported by the literature, incidence of SBBO in this group is challenging to
report. DiBaise et al. (2006) state that little is actually known about the prevalence of
SBBO due to diagnostic barriers. The literature speaks to the difficulty in diagnosing
SBBO due to the invasive nature of the diagnostic methods, therefore it is often
diagnosed presumptively based on clinical symptoms (DiBaise et al., 2006; Malik et al.,
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2011; Xie, 2011). Data from this project shows that in most cases antibiotics were
prescribed based on prior clinical suspicion from the outpatient provider at some time
before the hospitalization. Far fewer cases were prescribed antibiotics based on clinical
suspicion during the visit. Only two patients had confirmatory diagnostic testing with
duodenal aspiration, which the literature suggests is the gold standard testing method
(DiBaise et al., 2006; Sieczkowska et al., 2016; Xie, 2011).
The data did reveal inconsistencies in prescribing practices under these clinical
circumstances. The chart review of 146 admission visits showed that antibiotics were
prescribed or continued during an admission 47 times for SBBO. In five of those cases,
the patient received two antibiotics at the same time. The presence of any one risk factor,
any one symptom (p > 0.19), or the presence of multiple symptoms (p = 0.50) did not
directly correspond to the prescribing of antibiotics. The inconsistencies in prescribing
practices were noted in terms of patient identification and antibiotic selection.
The literature supports the use of antibiotics, specifically metronidazole,
nitazoxanide, rifaximin, and sulfamethoxazole/trimethoprim, to decrease the symptoms
associated with SBBO (Attar et al., 1999; Cole & Kocoshis, 2013; Di Stefano et al.,
2005; Lauritano et al., 2005; Lauritano et al., 2009). Other treatment modalities such as
bowel flushing, probiotics and prokinetics were reported, but without sufficient data to
support their efficiency. Consistent with the literature, data showed that patients at
CCHMC are prescribed metronidazole 65% of the time in cases of suspected SBBO
followed by nitazoxanide, rifaximin, and sulfamethoxazole/trimethoprim. Nonpharmacological treatment modalities were not reported. Despite the literature and
current practices, experts in the field are now moving away from prophylactic use of
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antibiotics. The risk of repeated or inappropriate antibiotic exposure may outweigh the
benefits leading to disruption of the fecal microbiome and antibiotic resistant bacteria.
A significant correlation was found between the presence of an ostomy and
incidence of CLA-BSI (p = 0.01). Incidence of CLA-BSI was not otherwise statistically
significant in relation to patient age (p = 0.65) or any other single risk factor. Data from
this project will be used to shape the way patients with ostomies and central venous
catheters are cared for moving forward at CCHMC.
There were several limitations to this project. The lack of relevant pediatric
literature was a barrier during the literature review phase. As most of the
recommendations for diagnosis and treatment are extrapolated from adult literature, such
had to be reviewed and considered for this project. The project was limited by the small
sample size. Expanding the chart review to a two-year period would likely have
produced more patients. The lack of documentation regarding symptom resolution
prohibited the analysis of this as an outcomes measure. Expanding the inclusion criteria
to include outpatient visits, may have revealed more succinct consistency in diagnosing
and prescribing practices. The outpatient providers are smaller in number compared to
the number of inpatient providers and are considered content experts with medical
practices focused solely on this population.
Despite the limitations, the project had many strengths. This project helped bring
to light the inconsistences in prescribing practices for SBBO at CCHMC. Identification
of such inconsistencies revealed an excess of $24,000 in medical costs associated with
unjustified antibiotic prescribing. Data also revealed an additional 106 hospital days and
$265,000 in inpatient hospital days associated with CLA-BSI requiring central venous
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catheter removal following a course of antibiotics for presumed SBBO. The findings
from this evidence-based project have supported the development and future
implementation of the BESt document. The findings support inconsistencies in patient
identification based on risk factors and symptoms of SBBO as well as inconsistencies in
prescribing practices. This lack of clinical consistency strengthens the need for
standardization of care.
This evidence-based project has implications for use beyond the focus of this
project. Based on the preliminary data shared, the antibiotic stewardship team at
CCHMC is interested in pursuing new clinical research aimed at DNA mapping for
future duodenal aspirates in pediatric patients with short bowel syndrome. DNA
mapping of duodenal aspirates will assist providers in targeted antibiotic selection based
on real time patient results. Over a period of time, enough samples may be collected that
will help guide antibiotic therapy preferences in general moving forward. At the time
DNA mapping is adopted, the BESt may need to be revised depending on the findings.
An additional implication for practice relates to central line care for patients with
an ostomy. CLA-BSI are tracked at CCHMC by medical unit and staff nurses receive
feedback relative to their unit performance. Based on data presented herein, there is now
great interest from nursing to take a closer look at central venous catheter care protocols
and modifying them for patients with ostomies with the goal to reduce future CLA-BSI in
these patients.
The absence of provider documentation was an incidental finding and a large
barrier to the project. Moving forward, there are plans to develop a prescribing order set
for SBBO antibiotics that will require providers to document the patient’s risk factors and
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presenting signs and symptoms. Activation of the order set can be linked to a
documentation reminder one week later that requires providers to answer to the resolution
of symptoms. These process improvements will improve the understanding the efficacy
of antibiotic treatment for pediatric patients with short bowel syndrome and SBBO.
In alignment with The Essentials for Doctoral Education for Advanced Nursing
Practice Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based
Practice, the DNP student is prepared to disseminate findings from evidence-based
practice and research to improve healthcare outcomes (Nursing, 2006). The ultimate goal
for this project is peer reviewed publication in a medical or nursing journal. However,
the completion of this goal will fall outside the timeframe of the academic plan of study
due to delays with IRB determination. Publishing in a peer reviewed journal is no small
feat, but successful submission and acceptance of a manuscript garners respect for the
published work and contributes to the scientific community. Evidence-based prescribing
recommendations have been drafted under the mentorship of gastroenterology and
infectious disease experts and will be proposed in the form of a BESt document for use
throughout the organization at CCHMC.
Patients with short bowel syndrome are complex and have many medical needs
making their care complicated and sometimes confusing. One condition that can be
detrimental to their health is SBBO. SBBO can be difficult to identify and even more
difficult to treat without pediatric clinical trials to support decision making. Based on a
one-year retrospective chart review, in-depth statistical analysis, and content expert
opinions, a BESt document has been drafted for implementation at CCHMC providing a
framework from which to make clinical decisions. Patients with SBBO may benefit from
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antibiotic therapy and deserve that opportunity when indicated, but equally as valuable is
avoiding antibiotic exposure in patients who do not have a clear indication for treatment.
It is a providers’ responsibility to understand the difference to the best of their ability and
prescribe accordingly, this project will facilitate that for pediatric patients with short
bowel syndrome.
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Appendix A
Database Search/Keywords
Keyword(s), subject,
headings, MeSH terms
small bowel bacterial
overgrowth, small intestine
bacterial overgrowth, SBBO,
SIBO, blind loop syndrome,
antibiotic, prophylactic
antibiotic, antibacterial
agents, or anti-infective
agents
"Intestine,
Small/microbiology"[MAJR]
AND "humans"[MeSH
Terms]) AND ("AntiBacterial Agents "[MeSH]
AND "humans"[MeSH
Terms]) AND
"humans"[MeSH Terms]
AND
Small bowel bacterial
overgrowth AND antibiotics

Database

Limits
applied

Cochrane
Database
for
Systematic
Reviews

2006 to
present,
English
language

Listed
0
systematic
review

Reviewed Used
7
2

1 metaanalysis

PubMed

2006 to
present,
English
language

CINAHL

2006 to
present,
English
language
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Number of hits

41 trials
59

17

9

12

2

2
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LEGEND Table of Evidence Levels
LEGEND
Let Evidence Guide Every New Decision

Table of Evidence Levels
TABLE OF EVIDENCE LEVELS:

Levels of Individual Studies by Domain, Study Design, & Quality

* a = good quality study
+

Published Expert
Opinion

2a/2b
3a/3b
4a/4b

5a
5b

5a
5b

5a
5b

5a
5b

5a
5b

5

5a
5b

5a
5b

5a
5b

5a
5b

5a
5b

5

5a
5b
5a
5b

5a
5b
5a
5b
5a
5b
5a
5b
5a
5b

5a
5b
5a
5b
5a
5b
5a
5b
5a
5b

5a
5b
5a
5b
5a
5b
5a
5b
5a
5b

5a
5b
5a
5b
5a
5b
5a
5b
5a
5b

2a/2b
3a/3b
4a/4b
2/3/4
a/b
2/3/4
a/b

2/3/4
a/b

b = lesser quality study

CCT = Controlled Clinical Trial

KAB = Knowledge, Attitudes, and Beliefs

RCT = Randomized Controlled Trial

Shaded boxes indicate study design may not be appropriate or commonly used for the domain of the clinical question.
Development for this table is based on:
1. Phillips, et al: Oxford Centre for Evidence-based Medicine Levels of Evidence, 2001. Last accessed Nov 14, 2007 from http://www.cebm.net/index.aspx?o=1025 .
2. Fineout-Overholt and Johnston: Teaching EBP: asking searchable, answerable clinical questions. Worldviews Evid Based Nurs, 2(3): 157-60, 2005.
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Local Consensus
Published Abstracts

Bench Study

2a
2b

Case Reports
N-of-1 Study

3a
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3a
3b

Guidelines

2a
2b
3a
3b
2a
2b

4a
4b

Decision Analysis
Economic Analysis
Computer Simulation

3a
3b

4a
4b

(PDSA)

2a
2b

4a
4b
4a
4b
4a
4b
4a
4b

3a
3b

4a
4b

Quality Improvement

4a
4b
4a
4b

4a
4b

2a
2b

(Before/After, Time Series)

4a
4b
4a
4b

4a
4b

Longitudinal

Psychometric Study

4a
4b

3a
3b

3a
3b

1a
1b

+
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4b

4a
4b

Mixed Methods Study

Prevalence

Descriptive Study
Epidemiology
Case Series

Incidence

Cross – Sectional

Etiology / Risk Factors

2a
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4a
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Case – Control

1a
1b
1a
1b
1a
1b
1a
1b

Prognosis

Meaning / KAB

2a
2b

4a
4b

Cohort
– Retrospective

1a
1b

3a
3b

Cohort
– Prospective

Diagnosis / Assessment

2a
2b

Qualitative Study

1a*
1b*

CCT +
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Intervention
Treatment, Therapy,
Prevention, Harm,
Quality Improvement

RCT +

DOMAIN OF
CLINICAL QUESTION

Meta–Synthesis

Systematic Review
Meta–Analysis

TYPE OF STUDY / STUDY DESIGN

5
5
5
5
5

Appendix C
Example LEGEND Critical Appraisal Form [Expert Opinion]

LEGEND: Evidence Appraisal of a Single Study
All Domains
Expert Opinion
Project/Topic of your Clinical Question:
Reviewer:
Article Title:
Year:

Today’s Date:

Final Evidence Level:

First Author:

Journal:

Do the aim/purpose/objectives assist in answering your clinical question?
• Aim/Purpose/Objectives:

Yes

No

Unknown

When reading the bolded questions, consider the bulleted questions to help answer the main question.
If you are uncertain of your skills in evidence evaluation, please consult a local evidence expert for assistance:
CCHMC Evidence Experts: http://groups/ce/NewEBC/EBDMHelp.htm
Unfamiliar terms can be found in the LEGEND Glossary: http://groups/ce/NewEBC/EBCFiles/GLOSSARY-EBDM.pdf

BASIC ELEMENTS OF AN EXPERT OPINION / REVIEW ARTICLE
1. Is the author a known expert in the field being studied?

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

• What are the author’s credentials?
Comments:

2. Does the author have a known bias?
Comments:

3. Is the patient population, problem, or issue clearly described?
Comments:

4. Is the literature search clearly described?
Comments:

5. Is the date range of the cited literature appropriate and current?
Comments:

6. What types of research are cited (e.g., animal model, basic science, clinical studies)?
Comments:

7. Is more than one point of view explained, reported, or referenced?
Comments:
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LEGEND: Evidence Appraisal of a Single Study
All Domains
Expert Opinion
8. Were any conclusions clearly presented in the article?

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

• If applicable, were any adverse events clearly described?
Comments:

9. Was there freedom from conflict of interest?
• Sponsor/Funding Agency or Authors
Comments:

APPLICABILITY: CAN I APPLY THIS EXPERT OPINION / GENERAL REVIEW INFORMATION?
10. Can the results be applied to my population of interest?

• Is the setting described in the article applicable to my population of interest?
• Do the patient outcomes apply to my population or question of interest?
• Were the patients in this article similar to my population of interest?
Comments:

11. Are my patient’s and family’s values and preferences satisfied by the knowledge
gained from this article (such as outcomes considered)?
Comments:

12. Would you include this article in development of a care recommendation?
Comments:

ADDITIONAL COMMENTS OR CONCLUSIONS (“TAKE-HOME POINTS”):

Copyright © 2006-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.
April 9, 2012
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library
Evidence-Based Decision Making – www.cincinnatichildrens.org/evidence
Page 2 of 3

76

LEGEND: Evidence Appraisal of a Single Study
All Domains
Expert Opinion
QUALITY LEVEL / EVIDENCE LEVEL
•
•

Consider each “No” answer and the degree to which this limitation is a threat to the validity of the results, then check the
appropriate box to assign the level of quality for this study/article.
Consider an “Unknown” answer to one or more questions as a similar limitation to answering “No,” if the information is not
available in the article.

THE EVIDENCE LEVEL IS:

Good Quality Expert Opinion / General Review
Lesser Quality Expert Opinion/General Review

[5a]
[5b]

Not Applicable
Table of Evidence Levels

+

Case Reports
N-of-1 Study

Bench Study

Published Expert Opinion

2/3/4
a/b

5a
5b

5a
5b

5a
5b

5a
5b

5a
5b

Local Consensus
Published Abstracts

Guidelines

(PDSA)

Decision Analysis
Economic Analysis
Computer Simulation

4a
4b

Quality Improvement

Descriptive Study
Epidemiology
Case Series

Cross – Sectional

(Before/After, Time Series)

Longitudinal

Case – Control

Cohort
– Retrospective

Cohort
– Prospective

Qualitative Study

Psychometric Study

CCT +

RCT +

1a
1b

Mixed Methods Study

All Domains

Meta–Synthesis

DOMAIN OF
CLINICAL
QUESTION

Systematic Review
Meta–Analysis

TYPE OF STUDY / STUDY DESIGN

RCT = Randomized Controlled Trial; CCT = Controlled Clinical Trial

Development for this appraisal form is based on:
1. Fineout-Overholt and Johnston: Teaching EBP: asking searchable, answerable clinical questions. Worldviews Evid Based Nurs, 2(3): 157-60, 2005.
2. Guyatt, G.; Rennie, D.; Evidence-Based Medicine Working Group.; and American Medical Association.: Users' guides to the medical literature : a manual for evidencebased clinical practice. Users' guides to the medical literature : a manual for evidence-based clinical practice: "JAMA & archives journals." Chicago, IL, 2002
3. Melnyk, B. M. and E. Fineout-Overholt (2005). Evidence-based practice in nursing & healthcare: a guide to best practice. Philadelphia, Lippincott Williams & Wilkins.
4. Phillips, et al: Oxford Centre for Evidence-based Medicine Levels of Evidence, 2001. Last accessed Nov 14, 2007 from http://www.cebm.net/index.aspx?o=1025.
5. Local Consensus
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5

Appendix C-continued
Example LEGEND Critical Appraisal Form [Systematic Review/Meta-analysis]

LEGEND: Evidence Appraisal of a Single Study
Intervention
Systematic Review / Meta-Analysis
Project/Topic of your Clinical Question:
Reviewer:
Article Title:
Year:

Today’s Date:

Final Evidence Level:

First Author:

Journal:

Do the study aim/purpose/objectives and inclusion/exclusion criteria assist in answering your clinical question?
Yes
No
Unknown
• Study Aim/Purpose/Objectives:
• Inclusion Criteria:
• Exclusion Criteria:

When reading the bolded questions, consider the bulleted questions to help answer the main question.
If you are uncertain of your skills in evidence evaluation, please consult a local evidence expert for assistance:
CCHMC Evidence Experts: http://groups/ce/NewEBC/EBDMHelp.htm
Unfamiliar terms can be found in the LEGEND Glossary: http://groups/ce/NewEBC/EBCFiles/GLOSSARY-EBDM.pdf

VALIDITY:

ARE THE RESULTS OF THE SYSTEMATIC REVIEW / META–ANALYSIS VALID OR CREDIBLE?

1. Did the overview address a focused clinical question?

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Comments:

2. Was the search for relevant studies detailed and exhaustive?
• Was it unlikely that important, relevant studies were missed?
Comments:

3. Did the systematic review use RCTs?
• Were the criteria used to select articles for inclusion appropriate?
• Was the assignment of patients to treatments randomized?
Comments:

4. Were the included studies appraised and assigned a high level of quality?
Comments:

5. Were the methods consistent from study to study?
• Were populations among the included studies comparable and appropriate?
• Were the outcomes, interventions, and exposures measured in the same way
in the groups being compared?
Comments:
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LEGEND: Evidence Appraisal of a Single Study
Intervention
Systematic Review / Meta-Analysis
6. Was there freedom from conflict of interest?
• Sponsor/Funding Agency or Investigators

Yes

No

Unknown

Comments:

RELIABILITY:

ARE THESE VALID STUDY RESULTS IMPORTANT?

7. What were the main results of the systematic review/meta-analysis? (e.g., Helpful data: Page #, Table #, Figures, Graphs)

•

What was the effect size? (How large was the treatment effect?)

•

What were the measures of statistical uncertainty (e.g., precision)?
(Were the results presented with Confidence Intervals or Standard Deviations?)

8. Were the results statistically significant?

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Yes

No

Unknown

Comments:

9. Were the results clinically significant?
• If potential confounders were identified, were they discussed in relationship
to the results?
Comments:

10. Were adverse events discussed?
Comments:

APPLICABILITY:

CAN I APPLY THESE VALID, IMPORTANT STUDY RESULTS TO TREATING MY PATIENTS?

11. Can the results be applied to my population of interest?
• Is the treatment feasible in my care setting?
• Do the patient outcomes apply to my population or question of interest?
• Are the likely benefits worth the potential harm and costs?
• Are the patients in this study similar to my population of interest?
Comments:

12. Are my patient’s and family’s values and preferences satisfied by the treatment
and its consequences?
Comments:
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LEGEND: Evidence Appraisal of a Single Study
Intervention
Systematic Review / Meta-Analysis
13. Would you include this study/article in development of a care recommendation?

Yes

No

Unknown

Comments:

ADDITIONAL COMMENTS OR CONCLUSIONS (“TAKE-HOME POINTS”):

QUALITY LEVEL / EVIDENCE LEVEL
•
•

Consider each “No” answer and the degree to which this limitation is a threat to the validity of the results, then check the
appropriate box to assign the level of quality for this study/article.
Consider an “Unknown” answer to one or more questions as a similar limitation to answering “No,” if the information is not
available in the article

THE EVIDENCE LEVEL IS:

Good Quality Systematic Review
Lesser Quality Systematic Review

[1a]
[1b]

Not Valid, Reliable, or Applicable
Table of Evidence Levels

+

2/3/4
a/b

5a
5b

5a
5b

5a
5b

5a
5b

5a
5b

Local Consensus
Published Abstracts

Published Expert Opinion

4a
4b

Bench Study

4a
4b

Case Reports
N-of-1 Study

4a
4b

Guidelines

4a
4b

Decision Analysis
Economic Analysis
Computer Simulation

4a
4b

Mixed Methods Study

4a
4b

(PDSA)

Case – Control

3a
3b

Quality Improvement

Cohort
– Retrospective

4a
4b

Descriptive Study
Epidemiology
Case Series

Cohort
– Prospective

3a
3b

Cross – Sectional

Qualitative Study

2a
2b

(Before/After, Time Series)

CCT +

1a
1b

Intervention
Treatment, Therapy,
Prevention, Harm,
Quality Improvement

Longitudinal

RCT +

DOMAIN OF
CLINICAL
QUESTION

Systematic Review
Meta–Analysis

TYPE OF STUDY / STUDY DESIGN

5

RCT = Randomized Controlled Trial; CCT = Controlled Clinical Trial

Development for this appraisal form is based on:
1. Guyatt, G.; Rennie, D.; Evidence-Based Medicine Working Group.; and American Medical Association.: Users' guides to the medical literature : a manual for evidencebased clinical practice. Users' guides to the medical literature : a manual for evidence-based clinical practice: "JAMA & archives journals." Chicago, IL, 2002
2. Melnyk, B. M. and E. Fineout-Overholt (2005). Evidence-based practice in nursing & healthcare : a guide to best practice. Philadelphia, Lippincott Williams & Wilkins.
3. Lohr, K. N. and T. S. Carey (1999). "Assessing "best evidence": issues in grading the quality of studies for systematic reviews." Joint Commission Journal on Quality
Improvement 25(9): 470-9.
4. Fineout-Overholt, E. and L. Johnston (2005). "Teaching EBP: asking searchable, answerable clinical questions." Worldviews Evid Based Nurs 2(3): 157-60.
5. Jerosch-Herold, C. (2005). "An evidence-based approach to choosing outcome measures: a checklist for the critical appraisal of validity, reliability and responsiveness
studies." British Journal of Occupational Therapy 68(8): 347-53.
6. Phillips, et al: Oxford Centre for Evidence-based Medicine Levels of Evidence, 2001. Last accessed Nov 14, 2007 from http://www.cebm.net/index.aspx?o=1025.
7. Fineout-Overholt and Johnston: Teaching EBP: asking searchable, answerable clinical questions. Worldviews Evid Based Nurs, 2(3): 157-60, 2005.
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Appendix D
LEGEND Grading the Body of Evidence
LEGEND
Let Evidence Guide Every New Decision

Grading the Body of Evidence
Grade

Method
Step 1
(see worksheet to
summarize the body of
evidence)

High
(if the studies didn’t fit
neatly into a box in
step 1)

•
•
•
•
•

Confirmation Step

Further research is unlikely to change our confidence in the answer to the clinical question.

Step 2

Sufficient number of
high quality studies
with consistent*
results

Step 1

NUMBER OF STUDIES
1
3+
5+

(see worksheet to
summarize the body of
evidence)

Step 2

Moderate

A single well-done
study or
Multiple studies of
lesser quality or with
some uncertainty

(if the studies didn’t fit
neatly into a box in
step 1)

Confirmation Step

Further research is likely to have an important impact on our confidence in the precision of the answer
to the clinical question, and may even change the answer itself.

(see worksheet to
summarize the body of
evidence)

(if the studies didn’t fit
neatly into a box in
step 1)

Confirmation Step

NUMBER OF STUDIES
1+

Step 2

QUALITY OF STUDIES*
Insufficient quality to meet
Moderate criteria above

CONSISTENCY OF RESULTS*
Yes

Local opinion or
5
Yes
Published non-research articles
• health professional opinion is the only relevant published information
• local consensus is clear
• uncertainty due to either
• validity threats (generalizability, bias, design flaws or adequacy of statistical power) or
• inconsistency
There is published and/or local consensus, but little or no research, to answer the clinical question.
Further research is very likely to have an important impact on the answer.

Step 1

Grade
Not Assignable

CONSISTENCY OF RESULTS*
NA
Yes
Yes

Or
• multiple studies
• weaker designs for answering the question addressed
• consistent results with minor exceptions at most

Step 2
Studies with
insufficient quality
including case
reports, case studies,
general reviews, and
local consensus

QUALITY OF STUDIES*
2a
1, 2, 3; a or b
1, 2, 3, 4; a or b

Either
• multiple studies
• strong designs for answering the question addressed
• some uncertainty due to either
• validity threats (generalizability, bias, design flaws or adequacy of statistical power) or
• inconsistency

Step 1

Low

NUMBER OF STUDIES
QUALITY OF STUDIES*
CONSISTENCY OF RESULTS*
1
1a
NA
2+
1a or 2a
Yes
5+
1a, 2a, or 3a
Yes
5+
1a, 1b, 2a, or 2b
Yes
multiple studies, unless large effect and very clinically important
strong designs for answering the question addressed
clinically important and consistent results with minor exceptions at most
free of any significant doubts about validity
(generalizability, bias, design flaws)
adequate statistical power
(including studies showing no difference)

NUMBER OF STUDIES
0+
Local opinion
•

QUALITY OF STUDIES*
Any evidence level
5

CONSISTENCY OF RESULTS*
No
No

studies have not been done, or

(if the studies didn’t fit
Insufficient design or
•
published studies are seriously flawed, and/or
neatly into a box in
execution, too few
•
published studies give inconsistent results
step 1)
studies, inconsistent
Confirmation Step
results, and lack of
There is insufficient evidence and lack of consensus to answer the clinical question.
consensus
*Note: When there is both high and low quality evidence and the results are inconsistent:
• Disregard lower quality evidence if the lower quality evidence is inconsistent with all higher quality evidence.
• Avoid disregarding lower quality evidence when inconsistency is at multiple quality levels, because bias could be introduced when determining which evidence to disregard.
Some of the concepts for this development are based on: Atkins et al: Grading quality of evidence and strength of recommendations. BMJ, 328(7454): 1490, 2004;
Briss et al: Developing an evidence-based Guide to Community Preventive Services--methods. The Task Force on Community Preventive Services. Am J Prev Med, 18(1 Suppl): 35-43, 2000; &
Greer et al: A practical approach to evidence grading. Jt Comm J Qual Improv, 26(12): 700-12, 2000.
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Appendix E
LEGEND Judging the Strength of a Recommendation

LEGEND
Let Evidence Guide Every New Decision

Judging the Strength of a Recommendation
Project Title:

Date:

In determining the strength of a recommendation, the development group makes a considered judgment.
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience,
and other dimensions. The development group will consider what the relative weight each dimension listed below
contributes when determining the strength of a recommendation.
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates
support for a stronger recommendation, complete one of the sentences below to judge the strength of this
recommendation.
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.)
It is strongly recommended that…
It is recommended that…
There is insufficient evidence and a lack of
consensus to make a recommendation on…

Dimensions
1. Grade of the Body of Evidence

High grade evidence

Moderate grade
evidence

Low grade evidence

2. Safety / Harm

Has minimal adverse
effects

Has moderate adverse
effects

Has serious adverse
effects

3. Benefit to target population

Has significant benefit

Has moderate benefit

Has minimal benefit

Low burden of
adherence

Unable to determine
burden of adherence

High burden of
adherence

Cost-effective to
healthcare system

Inconclusive economic
effects

Not cost-effective to
healthcare system

Evidence directly
relates to
recommendation for
this target population.

There is some concern
about the directness of
evidence as it relates
to the recommendation for this target
population.

Evidence only
indirectly relates to
recommendation for
this target population.

High impact on
morbidity, mortality,
or quality of life

Medium impact on
morbidity, mortality,
or quality of life

Low impact on
morbidity, mortality,
or quality of life

(e.g., health benefit to patient)

4. Burden on population to adhere
to recommendation
(e.g., cost, hassle, discomfort, pain,
motivation, ability to adhere, time)

5. Cost-effectiveness to healthcare
system
(e.g., balance of cost/savings of
resources, staff time, supplies based
on published studies/onsite analysis)

6. Directness
(the extent to which the body of
evidence directly answers the clinical
question [population/problem,
intervention, comparison, outcome])

7. Impact on morbidity, mortality,
or quality of life

Some of the concepts for this development based on:
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6,
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005.
Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.
June 11, 2012
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library |
Occupational Therapy & Physical Therapy | Hospital Medicine
www.cincinnatichildrens.org/evidence

82

Appendix F
Summary of Pediatric Literature
EBDM Evidence Summary Table
CHARACTERISTICS | RESULTS | CONCLUSIONS | EVIDENCE LEVELS

Study Type
Study Citation
Reed, 2014

N
Sample Size

TITLE, IF APPLICABLE OR IF MULTIPLE TABLES
Population
Intervention / Comparison Groups

Significant Results

Conclusions

Including estimates with associated precision (e.g., Odds Ratios or NNT with Confidence Intervals)

Including Limitations, Gaps, Applicability, or other Notes

Expert opinion

NA

Pediatrics with SBBO and short bowel
syndrome

NA

NA

Expert opinion

NA

Patients with SBBO and short bowel
syndrome

NA

NA

Malik, 2011

Expert opinion

Pediatrics with SBBO and intestinal failure

NA

Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved.
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm
James M. Anderson Center for Health Systems Excellence

NA

5a

Recommendations on the basis
of clinical experience is
necessary
May require trial and error approach to antibiotic therapy.
Antimicrobial therapy should provide coverage for both aerobic and
anaerobic organisms, monotherapy against anaerobes should be
avoided

NA

Evidence
Level

Prompt diagnosis and
treatment of SBBO can
improve the nutrition status of
pediatric pts with SBS
Amox-clav acid 10 mg/kg/dose twice daily
Ciprofloxacin 10-20 mg/kg/dose twice daily
Clindamycin 10-30 mg/kg/d divided three times per day
Doxycycline 100 mg twice daily (only >8 yr old)
Metronidazole 10 mg/kg/dose twice daily
Neomycin 50 mg/kg/d divided every 6 hours
Tetracycline 25-50 mg/kg/d divided every 6 hours (only >8yr old)
Vancomycin 10 mg/kg/dose every 6 hours

83
DiBaise, 2006

Outcomes

(Setting, Patients)

5a

For cases in which a firm dx
cannot be made, but clinical
symptoms favor SBBO –
empiric antibiotics may be a
more cautious approach
Trimethoprim/sulfa 2-10 mg/kg/dose twice daily
Metronidazole 10 mg/kg/dose twice daily
Amox-clav acid 15 mg/kg/dose twice daily
Rifaxamin 10-15 mg/kg/dose twice daily
Tetracycline 10-15 mg/kg/dose twice daily (only >8 yr old)
Ciprofloxacin 10-10 mg/kg/dose twice daily
Gentamicin 5 mg/kg/dose twice daily
Neomycin 2.5 mg/kg/dose four times daily

5a

EBDM Evidence Summary Table
CHARACTERISTICS | RESULTS | CONCLUSIONS | EVIDENCE LEVELS
Cole, 2007

Expert opinion

NA

Pediatrics with SBBO and short bowel
syndrome

NA

NA

Quigley, 2006

Expert opinion

Antibiotics: Metronidazole, Bactrim, Augmentin, Rifaximin, Cipro,
Chloramphenicol, Doxycycline, Neomycin, and Norfloxacin
Probiotics: Lactobacillus species, Bifidobacterium species, Bacillus
cereus, Enterococcus faecalis, E coli Nissle 1917, Saccharomyces
boulardii, Saccaromyces cerevisiae, and Streptococcus thermophiles
NA

Patients with SBBO

NA

NA

Ching, 2007

Expert opinion

Current understanding of
bacterial in the intestines and
issues related to SBBO

Management of patients with
SBBO remains for the most
part primarily empiric and
comprises of antibiotic therapy
and correction of nutritional
deficiencies
Antibiotics: Augmentin, Cipro, Chloramphenicol, Doxycycline,
Metronidazole, Neomycin, Norfloxacin, Tetracycline, Bactrim, and
Rifaximin

NA

Pediatrics with IF and SBBO

NA

Cole, 2013

Expert opinion

Antibiotics: Amphotericin, Augmentin, Cipro, Clindamycin, Colistin,
Doxycycline, Gentamicin, Metronidazole, Neomycin, Tetracycline,
Tobramycin, Rifaximin, and Vancomycin
NA

Pediatrics with surgical short bowel and IF
with SBBO

Shah, 2013

Meta-analysis

NA

311

Pediatrics and adults with SBBO or SBBO
symptoms

Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved.
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm
James M. Anderson Center for Health Systems Excellence

5a

There are no large scale clinical
trials evaluating the timing and
effectiveness of antibiotics for
SBBO

Metronidazole is the most popular agent for eradicating
anaerobes.
Nitazoxanide and rifaximin over obligate anaerobes effectively.
Bactrim, Gent, extended spectrum PCN, and cephalosporins
cover putrefactive gram neg aerobes.
Augmentin effective against 90% of isolated species

NA

5a

Short courses of oral
antibiotics are the mainstay of
therapy in SBBO

84
NA

5a

Rifaximin vs placebo; rifaximin vs rifaximin plus additive;
rifaxamin vs metronidazole; different rifaximin doses;
metronidazole vs Cipro; neomycin vs placebo; rifaximin vs
chlortetracycline

5a

EBDM Evidence Summary Table
CHARACTERISTICS | RESULTS | CONCLUSIONS | EVIDENCE LEVELS
Rifaximin overall breath test normalization rate of 49.5% (95% CI, CI 44.0 – 55.1)
Antibiotics were more effective than placebo with combined breath test
normalization rate of 51.1% (95% CI 46.7-55.5) compared to 9.8% (95% Ci 4.6-17.8
for placebo)
Meta-analysis of 4 studies favoured abx over placebo for breath test normalization
with OR 2.55 (95% CI, 1.29-5.04)

Sentongo, 2008

Expert opinion

NA

Pediatrics with SBBO

NA

NA

85

Sieczkowska, 2016

Expert opinion

NA

Pediatrics with SBBO

NA

Case series

Pediatrics with SBBO

Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved.
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm
James M. Anderson Center for Health Systems Excellence

NA

5a

Further research is needed to
determine the clinical impact
of SBBO and establish
diagnostic and therapeutic
guidelines
Treatment goals: correct underlying disease or defect, eliminate
predisposing conditions, replete nutrition, modify microbiota with
antibiotics or probiotics
One pediatric study of 20 children showed effective treatment with 14
day course of Bactrim and metronidazole
Rifaximin studied in children with CAP and IBS
No official recommendations, too little data available
A non-absorbable antibiotic, like rifaximin, with a low incidence of side
effects seems to be the best option for first-line treatment, especially in
pediatrics

6

1a

Definitive therapy in patients
with recurring symptoms is
correction of the predisposing
factor; otherwise,
management is mostly
supportive
Treatment of SBBO: 1) antibiotics and prophylaxis; 2) dietary
approaches; 3) probiotics; 4) corrective or palliative surgery
Avoid antibiotics with poor activity against enteric anaerobes or oral
aminoglycosides
Commonly used are metronidazole (bacteroides and anaerobic
coverage), Bactrim (broad spectrum), and rifaximin (anaerobic coverage
and non-absorbable)

NA

Vanderhoof, 1998

Antibiotics appear to be more effective than placebo for breath test
normalization in patients with SBBO symptoms; and breath test
normalization may correlate with clinical response

5a

Relief of SBBO symptoms not
relieved with abx therapy

EBDM Evidence Summary Table
CHARACTERISTICS | RESULTS | CONCLUSIONS | EVIDENCE LEVELS
NA

Youssef, 2012

Expert opinion

Six patients with SBBO who did not respond to antibiotic therapy and
required additional medical or surgical interventions
Metronidazole may be used against facultative anaerobes with widest
popularity as well as Bactrim, aminoglycosides such as Gent, extended
spectrum PCN and cephalosporins
NA

Pediatrics with SBBO and short bowel
syndrome

NA

NA

86

Dehmer, 2011

Expert opinion

NA

Pediatrics with SBBO and short bowel
syndrome

Expert opinion

NA

Pediatrics with SBBO

NA

Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved.
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm
James M. Anderson Center for Health Systems Excellence

Scientific and clinical climate is
ripe for more information
about molecular
characterization of the
microbiome of short bowel
syndrome patients, so that
antimicrobials can be tailored
In Pediatric Intestinal Rehab Programs, it is commonplace to empirically
treat patient with short bowel syndrome and classic symptoms of SBBO
or an anatomic predisposition to SBBO with an enteral decontaminant
Antimicrobials are often cycled for 1-2 weeks each month
Other management considerations include glutamine and probiotics,
but the risks/benefits remain unclear
Treatment of SBBO in pediatric patients with short bowel syndrome is
largely unscientific and typically empiric

5a

Suggested antibiotics: metronidazole, sulfamethoxazole/trimethoprim,
aminoglycoside, amoxicillin-clavulanic acid, and rifiaximin

5a

NA

NA

Vanderhoof, 2003

5a

NA

Treatment aimed to decrease
bacterial replication with
antibiotics or surgically correct
anatomic anomaly
Suggested antibiotics: metronidazole, sulfamethoxazole/trimethoprim,
gentamycin, extended spectrum penicillin, tetracycline
Suggested non-antibiotic approaches: polyethylene glycol

5a

87
DiBaise 2006

Totals
√

1

Youssef 2012

1
1
√
√

Cole 2007
√

Cole 2013
√

Dehmer 2011
√

Sieczkowska 2016
√

1
8

Shah 2013

√

4
√

Malik 2011
√
√

Quigley 2006
√
√

Reed 2014
√
√

7
2

Doxycycline
Gentamicin
Metronidazole
Neomycin

√
√
√
√
√
√

√
√
√

√

√
√

2
1
√

Sentongo 2008

√

4
6
√

√

√

√
√

√
√
√

√
√
√

√
√
√

√

11
6

√

1

√

3

√
√

√

√
√

Vanderhoof 1998
√
√
√
√
√

Vanderhoof 2003
√
√
√
√

3

Tetracycline
Tobramycin

√
√
√

√

√

√

9
5
1

√
√

√
√

√
√

√
√
√

√
√

√

√

9

Bowel irrigation - Polyethylene glycol

√
√

√

√

√
√

√
√

√

2
5
4

√
√

√

√

1

Prokinetic agents

√
√

√

√
√

√
√
√
√

√
√
√

√

√

11

√

√

√

3

Surgical correction of dilated bowel

Probiotics

Glutamine

Antibiotic treatment options

Dietary changes

Vancomycin

Trimethoprim/sulfamethoxazole

Rifaximin

Penicillin, extended spectrum

Norfloxacin

Nitazoxanide

Colistin

√

Clindamycin

Chloramphenicol

Ciprofloxacin

Cephlasporins

Amoxicillin-clavulanic acid

Ching 2007
Amphotericin

Antimicrobials

Anaerobic coverage

Aerobic coverage

Appendix G

Pediatric Literature Synthesis Table
Non-antibiotic
treatment options

√

√

√

√

√
√

√

√
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Appendix H
Summary of the Adult Literature
EBDM Evidence Summary Table
CHARACTERISTICS | RESULTS | CONCLUSIONS | EVIDENCE LEVELS

Study Type
Study Citation
DiStefano, 2005

N
Sample Size

TITLE, IF APPLICABLE OR IF MULTIPLE TABLES
Population
Intervention / Comparison Groups

Significant Results

Conclusions

Including estimates with associated precision (e.g., Odds Ratios or NNT with Confidence Intervals)

Including Limitations, Gaps, Applicability, or other Notes

CCT

21

Adults with SBBO

Rifaximin followed by Flagyl; Rifaximin course x 2; Flagyl
course x 2

Both drugs reduced H2 breath test excretion values, but significantly lower after
Flagyl; both drugs induced a significant improvement in symptoms severity but the
reduction was significantly higher after Flagyl

Lauritano, 2005

88

Prospective
cohort

90

Adults with SBBO

Longitudinal

10

Adults with SBBO-related diarrhea

Daily stool frequency similar during control and placebo; Norfloxacin and amox-clav
acid led to a significant reduction in daily stool frequency (P<0.01 vs placebo).
Breath-expired H2 volume decreased with norfloxacin and amox-clav

Bohm, 2013

Expert opinion

N/A

Adults with SBBO

N/A

Lauritano, 2009

Prospective
randomized trial

Adults with SBBO (IBS or other functional
disorder)

Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved.
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm
James M. Anderson Center for Health Systems Excellence

4a

Management includes:
identifying and correcting
underlying causes, addressing
nutrition deficiencies,
implementing diet
modification, and using abx
Amox-clav acid and norfloxacin have been shown to reduce stool
frequency; Flagyl and Cipro have been effective for SBBO with Crohn’s.
Rifaximin is better at reducing breath test but not better than placebo
for reducing symptoms associated with celiac disease and ab pain in
children

135

3b

Norfloxacin and amox-clav acid
are effective in the treatment
of SBBO

Norfloxacin and amox-clav acid reduce the number of stools and
abnormal bacterial metabolic activity in SBBO-related diarrhea

N/A

3a

Higher dose of rifaximin had
greater normalization of
glucose breath test

Higher doses was effective without increasing side effects

Five 7-day treatment periods: untreated (control), placebo,
then in random and blinded fashion, norfloxacin (800
mg/d), amoxicillin-clavulanic acid (1500 mg/d), and
Saccharomyces boulardii (1500 mg/d)

Evidence
Level

Flagyl is more effective than
Rifaximin in the treatment of
SBBO

Both drugs improved symptoms, the effect was significantly better with
Flagyl

Rifaximin 600 mg/d vs 800 mg/d vs 1200 mg/d

Glucose breath test normalization was significantly higher in the 1200 mg/d group
(60%) with respect to group 1 (17%; P <0.001) and group 2 (27%, P<0.01)

Attar, 1999

Outcomes

(Setting, Patients)

Patients were randomized to two 7-day treatment groups:
rifaximin 1200 mg/d and metronidazole 750 mg/d

5b

Rifaximin showed a higher
SBBO decontamination rate
than metronidazole

EBDM Evidence Summary Table
CHARACTERISTICS | RESULTS | CONCLUSIONS | EVIDENCE LEVELS
Glucose breath tests normalization rate was significantly higher in the rifaximin
group compared to the metronidazole group (63.4% vs 43.7%, p<0.05, OR 1.50, 95%
CI 1.14-4.38)

Parrish, 2015

Expert opinion

N/A

Adults with SBBO and short bowel syndrome

N/A

89
Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved.
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm
James M. Anderson Center for Health Systems Excellence

N/A

The overall prevalence of adverse events was significantly lower in
rifaximin group compared to metronidazole group. Rifaximin had better
decontamination rates

3a

Excessive bacteria in the small
bowel can induce
inflammatory and atrophic
changes in the gut impairing
absorption, deconjugate bile
acids resulting in fat
maldigestion, consume vitamin
B12 leading to deficiency,
cause gas-related symptoms,
and aggravate diarrhea
Antimicrobial treatment is often empirically prescribed with success
judged on improvements in symptoms, reduction in stool output and/or
weight gain.
Amoxcillin-clavulanate 500 mg 2-3 times daily
Cephalexin 250 mg 2 times daily
Ciprofloxacin 500 mg 2 times daily
Doxycycline 100 mg 2 times daily
Metronidazole 250 mg 3 times daily
Neomycin 500 mg 2 times daily
Norfloxacin 400 mg 2 times daily
Rifaximin 250-500 mg 2-3 times daily
Tetracycline 250-500 mg 4 times daily
Trimethoprim-Sulfamethoxazole 1 double-strength tablet 2 times daily

5a

Appendix I
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Appendix J
Completed LEGEND Judging the Strength of a Recommendation
LEGEND
Let Evidence Guide Every New Decision

Judging the Strength of a Recommendation
Project Title:

The use of antibiotic therapy to treat small bowel bacterial
overgrowth in the pediatric population with short bowel syndrome
Recommendation 1: Identify risk factors for SBBO

Date:

5/5/2017

In determining the strength of a recommendation, the development group makes a considered judgment.
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience,
and other dimensions. The development group will consider what the relative weight each dimension listed below
contributes when determining the strength of a recommendation.
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates support for a
stronger recommendation, complete one of the sentences below to judge the strength of this recommendation.
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.)
x

It is strongly recommended that … risk factors for
SBBO be identified
It is recommended that…
There is insufficient evidence and a lack of
consensus to make a recommendation on…
Dimensions

1. Grade of the Body of Evidence

High grade evidence

Moderate grade
evidence

x

Low grade evidence

2. Safety / Harm

x

Has minimal adverse
effects

Has moderate adverse
effects

Has serious adverse
effects

3. Benefit to target population
(e.g., health benefit to patient)

x

Has significant benefit

Has moderate benefit

Has minimal benefit

4. Burden on population to adhere to
recommendation
(e.g., cost, hassle, discomfort, pain,
motivation, ability to adhere, time)

x

Low burden of
adherence

Unable to determine
burden of adherence

High burden of
adherence

5. Cost-effectiveness to healthcare
system
(e.g., balance of cost/savings of
resources, staff time, supplies based
on published studies/onsite analysis)

x

Cost-effective to
healthcare system

Inconclusive economic
effects

Not cost-effective to
healthcare system

6. Directness
(the extent to which the body of
evidence directly answers the clinical
question [population/problem,
intervention, comparison, outcome])

x

Evidence directly
relates to
recommendation for
this target population.

There is some concern
about the directness of
evidence as it relates to
the recommendation for
this target population.

Evidence only
indirectly relates to
recommendation for
this target population.

7. Impact on morbidity, mortality, or
quality of life

x

High impact on
morbidity, mortality, or
quality of life

Medium impact on
morbidity, mortality, or
quality of life

Low impact on
morbidity, mortality, or
quality of life

Some of the concepts for this development based on:
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6,
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005.
Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.
June 11, 2012
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library |
Occupational Therapy & Physical Therapy | Hospital Medicine
www.cincinnatichildrens.org/evidence
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LEGEND
Let Evidence Guide Every New Decision

Judging the Strength of a Recommendation
Project Title:

The use of antibiotic therapy to treat small bowel bacterial
overgrowth in the pediatric population with short bowel syndrome
Recommendation 1: Identify signs and symptoms of SBBO

Date:

5/5/2017

In determining the strength of a recommendation, the development group makes a considered judgment.
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience,
and other dimensions. The development group will consider what the relative weight each dimension listed below
contributes when determining the strength of a recommendation.
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates support for a
stronger recommendation, complete one of the sentences below to judge the strength of this recommendation.
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.)
x

It is strongly recommended that … signs and
symptoms of SBBO be identified
It is recommended that…
There is insufficient evidence and a lack of
consensus to make a recommendation on…
Dimensions

1. Grade of the Body of Evidence

High grade evidence

Moderate grade
evidence

x

Low grade evidence

2. Safety / Harm

x

Has minimal adverse
effects

Has moderate adverse
effects

Has serious adverse
effects

3. Benefit to target population
(e.g., health benefit to patient)

x

Has significant benefit

Has moderate benefit

Has minimal benefit

4. Burden on population to adhere to
recommendation
(e.g., cost, hassle, discomfort, pain,
motivation, ability to adhere, time)

x

Low burden of
adherence

Unable to determine
burden of adherence

High burden of
adherence

5. Cost-effectiveness to healthcare
system
(e.g., balance of cost/savings of
resources, staff time, supplies based
on published studies/onsite analysis)

x

Cost-effective to
healthcare system

Inconclusive economic
effects

Not cost-effective to
healthcare system

6. Directness
(the extent to which the body of
evidence directly answers the clinical
question [population/problem,
intervention, comparison, outcome])

x

Evidence directly
relates to
recommendation for
this target population.

There is some concern
about the directness of
evidence as it relates to
the recommendation for
this target population.

Evidence only
indirectly relates to
recommendation for
this target population.

7. Impact on morbidity, mortality, or
quality of life

x

High impact on
morbidity, mortality, or
quality of life

Medium impact on
morbidity, mortality, or
quality of life

Low impact on
morbidity, mortality, or
quality of life

Some of the concepts for this development based on:
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6,
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005.
Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.
June 11, 2012
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library |
Occupational Therapy & Physical Therapy | Hospital Medicine
www.cincinnatichildrens.org/evidence
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LEGEND
Let Evidence Guide Every New Decision

Judging the Strength of a Recommendation
Project Title:

The use of antibiotic therapy to treat small bowel bacterial
overgrowth in the pediatric population with short bowel syndrome
Recommendation 1: Identify antibiotics for the treatment of SBBO

Date:

5/5/2017

In determining the strength of a recommendation, the development group makes a considered judgment.
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience,
and other dimensions. The development group will consider what the relative weight each dimension listed below
contributes when determining the strength of a recommendation.
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates support for a
stronger recommendation, complete one of the sentences below to judge the strength of this recommendation.
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.)
x

It is strongly recommended that … antibiotics for
the treatment of SBBO be identified
It is recommended that…
There is insufficient evidence and a lack of
consensus to make a recommendation on…
Dimensions

1. Grade of the Body of Evidence

High grade evidence

x

Moderate grade
evidence

Low grade evidence

2. Safety / Harm

x

Has minimal adverse
effects

Has moderate adverse
effects

Has serious adverse
effects

3. Benefit to target population
(e.g., health benefit to patient)

x

Has significant benefit

Has moderate benefit

Has minimal benefit

Unable to determine
burden of adherence

High burden of
adherence

4. Burden on population to adhere to
recommendation
(e.g., cost, hassle, discomfort, pain,
motivation, ability to adhere, time)

Low burden of
adherence

x

5. Cost-effectiveness to healthcare
system
(e.g., balance of cost/savings of
resources, staff time, supplies based
on published studies/onsite analysis)

x

Cost-effective to
healthcare system

Inconclusive economic
effects

Not cost-effective to
healthcare system

6. Directness
(the extent to which the body of
evidence directly answers the clinical
question [population/problem,
intervention, comparison, outcome])

x

Evidence directly
relates to
recommendation for
this target population.

There is some concern
about the directness of
evidence as it relates to
the recommendation for
this target population.

Evidence only
indirectly relates to
recommendation for
this target population.

7. Impact on morbidity, mortality, or
quality of life

x

High impact on
morbidity, mortality, or
quality of life

Medium impact on
morbidity, mortality, or
quality of life

Low impact on
morbidity, mortality, or
quality of life

Some of the concepts for this development based on:
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6,
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005.
Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.
June 11, 2012
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library |
Occupational Therapy & Physical Therapy | Hospital Medicine
www.cincinnatichildrens.org/evidence
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Appendix K
Agency Approval form
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Appendix L
IRB Determination Cincinnati Children’s Hospital Medical Center
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Appendix M
IRB Determination Wright State
University
file:///Users/connorbrewer/Downloads/Initial approval-1.htm
Office of Research and Sponsored Programs
201J University Hall
3640 Col. Glenn Hwy.
Dayton, OH 45435-0001
(937) 775-2425
(937) 775-3781 (FAX)
e-mail: rsp@wright.edu

WSU IRB INITIAL APPROVAL – EXPEDITED REVIEW
Notification date:
PI:

IRB #:

September 15, 2017
Christina Heinzman,
Doctor of Nursing Practice
program
06124

Study expiration date:
September 14, 2018
Study approval date:
September 15, 2017
Expedited via category:

5

Title:
The role of antibiotic therapy in the treatment of small bowel bacterial
overgrowth in pediatric patients with short bowel syndrome
Approval
The Wright State University (WSU) IRB reviewed and approved the above study via
expedited review for 12 months at other location(s): Cincinnati Children's Hospital Medical
Center.
Waivers
The WSU IRB granted the following waivers for this study: Waiver of authorization and
consent.
Required Findings
The WSU IRB also found that this study met the following criteria for use of vulnerable
populations: Children 45 CFR 46.404.
Investigator Responsibilities
If this is a VA study, you must receive an additional approval letter from the VA R&D
Committee prior to initiating the study.
You must obtain IRB approval of any changes to this study prior to implementation.
You must receive continuing review of this study prior to the expiration date above.
If the study approval expires, you must not accrue additional subjects, collect data
and/or review medical records until proper renewal is obtained.
You must report any unanticipated problems or other problems/events in accordance
with WSU IRB policy.

1 of 2

5/12/18, 11:42
If you have questions regarding the review and approval of this study, please contact
JodiAM
Blacklidge at jodi.blacklidge@wright.edu or 937-775-3974.
Thank you,
The Wright State University IRB
OHRP #IRB00000034
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Appendix N
Data Collection Tool

Treatment

clinical suspicion

Treated

Small bowel biopsy

Breath test

Metabolic acidosis

97

Malabsorption

Diagnostics

Weight loss

Presence of signs/symptoms

Hemotochezia

Presence of risk factors

Diarrhea/Steatorrhea

CoRoute of
Presence
morbid
enteral
of CVC
Dx
feeds

Flatulence

Primary
Dx

Abdominal distention bloating

Dx

Diagnostic Measures

Abdominal pain

LOS

Dehydration

DC date

Nausea/Vomiting

Admt
date

Multi-factorial

Age

Functional

Gender

Anatomic

MRN

Risk Identification

Duodenal aspirate

Demographics

Abx

Regimen

Sequelae

Cost

Resolutio
Abx for
Line
CLA-BSI
Organism
n
SBBO
removed

LOS

Appendix O
Risk Factors & Signs and Symptoms

Attar 1999

√

Bohm 2013

√

√

√

Ching 2007

√

√

√

Cole 2007

√

√

√

Collins 2011

√

√

DiBaise 2006

√

√

DiStefano 2005

√

√

Gutierrez 2012

√

√

√

√

Metabolic acidosis

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

Malabsorption

Weight loss

Hemotochezia

Diarrhea/Steatorrhea

Flatulence

Feeding intolerance

Abdominal distention bloating

Abdominal pain

Dehydration

SIGNS & SYMPTOMS

Nausea/Vomiting

Multi-factorial

Functional

Anatomic

RISK
FACTORS

√

√

√

√

√

√

√

√
√

√

Lauritano 2005
Lauritano 2009

√

Malik 2011

√

√

√

Quigley 2006

√

√

√

Reed 2014

√

√

√

Parrish 2015

√
√
√
√
√

√ √
√
√ √
√ √
√

Vanderhoof 2003
Dehmer 2011
Sieczkowski 2016
Youssef 2012

√

√

Sentongo 2008
Cole 2013
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√

√

√

√
√

√

√

√

√

√

√

√ √
√

√ √
√

√
√ √ √

√ √
√
√ √
√ √

√
√
√
√

√ √
√
√
√ √ √
√

√
√
√
√

Best Evidence Statement – BESt
Appendix P
BESt Document Draft
June 5, 2018

Antibiotic therapy for small bowel bacterial overgrowth in pediatric
patients with short bowel syndrome/intestinal failure
INTRODUCTION / BACKGROUND
Patients with short bowel syndrome/intestinal failure are at risk for the development of small bowel bacterial
overgrowth, a serious consequence caused by overgrowth of bacteria in the small bowel resulting in symptoms
of abdominal pain, abdominal distention, feeding intolerance, malabsorption, weight loss and increased risk of
metabolic acidosis. Clinical studies assessing the role of antibiotic therapy in the pediatric population are nearly
non-existent forcing clinicians to rely on adult literature for guidance. Diagnostic testing methods are often
invasive and difficult to perform in pediatric patients leaving clinicians to diagnosis this condition based on
symptomology. Treatment is often prescribed based on clinical experience and published expert opinion.
Inconsistency in the diagnosis and medical treatment of small bowel bacteria overgrowth is problematic at
CCHMC. A one-year retrospective chart review of pediatric patients admitted to the Gastroenterology/Lumen
service at Cincinnati Children’s Hospital Medical Center between 5/1/2016-5/1/2017 was conducted. Final
analysis of the data revealed inconsistency in antibiotic prescribing methods and in many cases overprescribing.
A best evidence statement (BESt) has been drafted for publication throughout the institution with the intent to
standardize antibiotic prescribing practices for this population.
Definitions for terms marked with * and Abbreviations may be found in an Abbreviations and Definitions section below.

CLINICAL QUESTION
P
I
C
O

(Population/Problem)
(Intervention)
(Comparison)
(Outcome)

In pediatric patients with short bowel syndrome and signs/symptoms of SBBO
Does treatment with antibiotic therapy
Compared to no treatment
Affect the symptoms of abdominal distention, vomiting and increased stool output?

TARGET POPULATION FOR THE RECOMMENDATION
Inclusion Criteria
The population of interest includes pediatric patients with a diagnosis of short bowel syndrome or intestinal
failure secondary to omphalocele, gastroschisis, duodenal atresia, jejunal atresia, ileal atresia, necrotizing
enterocolitis, malrotation with volvulus, Hirschsprung’s disease, presence of an ostomy, or traumatic bowel
injury who have EITHER “symptoms” of small bowel bacterial overgrowth (SBBO) including nausea/vomiting,
dehydration, abdominal pain, abdominal distention/bloating/gas, diarrhea/steatorrhea, hematochezia, weight
loss, malabsorption or metabolic acidosis OR other “risk factors” including dysmotility, chronic pseudoobstruction, megacystis megacolon intestinal hypoperistalsis syndrome, radiation enteropathy, H pylori, proton
pump inhibitor use, hypochlorhydria, and total or subtotal gastrectomy, immunodeficiency, malnutrition,
parenteral nutrition dependence, or chronic pancreatitis.
Exclusion Criteria
Anyone who does not meet the above criteria is excluded from this recommendation.
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Best Evidence Statement – BESt
TARGET USERS FOR THE RECOMMENDATIONS
Target users include, clinical providers including but are not limited to physicians, residents, and nurse
practitioners.

EVIDENCE–BASED CARE RECOMMENDATION
Recommendation #1: It is strongly recommended that providers properly identify risk
factors for SBBO.

(Arnott, McNeill, &
Satsangi, 2003)

Dimensions of Judging the Recommendation Strength for providers
properly identify risk factors for SBBO.
1. Safety / Harm (Side Effects and Risks)
2. Health benefit to patient
3. Burden on population to adhere to recommendation
4. Cost-effectiveness to healthcare system
5. Directness of the evidence for this target population

Minimal
Significant
Low
Cost-effective
Directly relates

6. Impact on quality of life, morbidity, or mortality
7. Grade of the Body of Evidence

Positive
High

(See Evidence Table below; *GNA – Grade Not Assignable)

Overall Strength of the Recommendation:

Strong

Moderate

Moderate / Neutral
Moderate / Neutral
Unable to determine
Inconclusive
Some concern of directness
Moderate / Neutral
Moderate
Low
Weak

Serious
Minimal
High
Not cost-effective
Indirectly relates
Negative
Very Low

GNA*

Consensus Only

Given the dimensions above for each recommendation and that more answers to the left of the scales indicate support for
a stronger recommendation, the recommendation statements reflect the strength of each recommendation as judged by
the development group.
(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.)

Discussion/Synthesis of the Evidence and Dimensions for the Recommendation
Learning to identify risk factors has the potential for significant benefit to this population in terms of
morbidity, mortality and quality of life. The evidence presented to support this recommendation is largely
based on expert opinion, clinical experience, and literature review, as well as the limited pediatric research
available (Bohm, Siwiec, & Wo, 2013a; Chan, Parrish, & DiBaise, 2015; Ching, Gura, Modi, & Jaksic, 2007;
Cole & Ziegler, 2007; Collins & Lin, 2011; Dehmer, Fuller, & Helmrath, 2011; Di Stefano, Miceli, Missanelli,
Mazzocchi, & Corazza, 2005; DiBaise, Young, & Vanderhoof, 2006; Gutierrez et al., 2012; Lauritano et al.,
2009; Malik, Xie, Wine, & Huynh, 2011; Quigley & Quera, 2006; Reed, 2014; Vanderhoof, Young, &
Thompson, 2003). Knowing the risk factors for SBBO, has the potential to minimize overprescribing of
unnecessary antibiotics. Overprescribing leads to increased healthcare expenses while failure to comply with
antibiotic stewardship increases risk of multi-resistant organisms.
__________

Recommendation #2: It is strongly recommended that providers receive educational training in the
identification of the signs and symptoms of SBBO.
Dimensions of Judging the Recommendation Strength that providers receive educational
training in the identification of the signs and symptoms of SBBO
1. Safety / Harm (Side Effects and Risks)
2. Health benefit to patient
3. Burden on population to adhere to recommendation
4. Cost-effectiveness to healthcare system
5. Directness of the evidence for this target population

Minimal
Significant
Low
Cost-effective
Directly relates

Moderate / Neutral
Moderate / Neutral
Unable to determine
Inconclusive
Some concern of directness
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Serious
Minimal
High
Not cost-effective
Indirectly relates

Best Evidence Statement – BESt
6. Impact on quality of life, morbidity, or mortality
7. Grade of the Body of Evidence
(See Evidence Table below; *GNA – Grade Not Assignable)

Overall Strength of the Recommendation:

Strong

Positive
High
Moderate

Moderate / Neutral
Moderate
Low
Weak

Negative
Very Low

GNA*

Consensus Only

Given the dimensions above for each recommendation and that more answers to the left of the scales indicate support for
a stronger recommendation, the recommendation statements reflect the strength of each recommendation as judged by
the development group.
(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.)

Discussion/Synthesis of the Evidence and Dimensions for the Recommendation
Second, it is strongly recommended that providers receive educational training in the identification of the signs
and symptoms of SBBO (Bohm et al., 2013a; Chan et al., 2015; Ching et al., 2007; Cole & Ziegler, 2007;
Collins & Lin, 2011; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et al., 2006; Gutierrez et al., 2012;
Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014; Vanderhoof et al., 2003).
Identifying the signs and symptoms of SBBO also has the potential to have great impact on the quality of life
for those affected. Differentiating the signs and symptoms of SBBO from other etiologies will allow providers
to more quickly recognize when an antibiotic therapy is indicated and when it is not.
__________

Recommendation #3: It is recommended that providers receive educational training in the prescribing of
preferred antibiotics and doses for the treatment of SBBO.
Dimensions of Judging the Recommendation Strength that providers receive educational
training in the identification of the signs and symptoms of SBBO
1. Safety / Harm (Side Effects and Risks)
2. Health benefit to patient
3. Burden on population to adhere to recommendation
4. Cost-effectiveness to healthcare system
5. Directness of the evidence for this target population

Minimal
Significant
Low
Cost-effective
Directly relates

6. Impact on quality of life, morbidity, or mortality
7. Grade of the Body of Evidence

Positive
High

(See Evidence Table below; *GNA – Grade Not Assignable)

Overall Strength of the Recommendation:

Strong

Moderate

Moderate / Neutral
Moderate / Neutral
Unable to determine
Inconclusive
Some concern of directness
Moderate / Neutral
Moderate
Low
Weak

Serious
Minimal
High
Not cost-effective
Indirectly relates
Negative
Very Low

GNA*

Consensus Only

Given the dimensions above for each recommendation and that more answers to the left of the scales indicate support for
a stronger recommendation, the recommendation statements reflect the strength of each recommendation as judged by
the development group.
(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.)

Discussion/Synthesis of the Evidence and Dimensions for the Recommendation
Finally, it is recommended that providers receive educational training in the identification of suitable antibiotics
and doses for the treatment of SBBO (Attar et al., 1999; Bohm et al., 2013a; Chan et al., 2015; Ching et al.,
2007; Cole & Kocoshis, 2013; Cole & Ziegler, 2007; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et
al., 2006; Lauritano et al., 2005; Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014;
Sentongo, 2008; Shah, Day, Somsouk, & Sewell, 2013; Sieczkowska, Landowski, Kaminska, & Lifschitz,
2016; Vanderhoof, Young, Murray, & Kaufman, 1998; Vanderhoof et al., 2003; Youssef, Mezoff, Carter, &
Cole, 2012). This recommendation was given a strong recommendation. Based on the multitude of clinical
experiences, expert opinion, and the limited number of interventional studies available, there is a support for a
handful of specific antibiotics which have been shown to be effective in minimizing symptoms. Experts from
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Best Evidence Statement – BESt
the Division of Gastroenterology, Hepatology, & Nutrition and Infectious Diseases have reviewed the patient
population, literature and current prescribing practices. It is recommended that a provider choose from
metronidazole, nitazoxanide, rifaximin, or sulfamethoxazole/trimethoprim with doses/frequency described
below:
-

Metronidazole *** mg/kg every *** hours for *** days

-

Nitazoxanide *** mg/kg every *** hours for *** days

-

Rifaximin *** mg/kg every *** hours for *** days

-

Sulfamethoxazole/trimethoprim *** mg/kg every *** hours for *** days
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Algorithm for … (if applicable)
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ABBREVIATIONS AND DEFINITIONS
Abbreviations
SBBO – small bowel bacterial overgrowth

Definitions
Term(s) and definition(s)

IMPLEMENTATION
Applicability & Feasibility Issues
Text
Describe items that may positively or negatively impact the successful implementation of this recommendation, such as:
• Define potential facilitators and barriers within the practice setting that may help or hinder the implementation
• Facilitators (e.g., leadership support, strong evidence, staff education support)
• Barriers (e.g., systems not in place, resources not available, baseline data not available, not currently an organizational priority, unfamiliarity
with the quality improvement process)

• Determine potential resource needs (e.g., cost, equipment availability, appropriate staff availability)

Relevant CCHMC Tools
Text
Identify tools or processes which need to be developed, adapted, or revised for incorporation of the recommendation into
practice (e.g., clinical pathways, order sets, EPIC/EMR, family education materials, Knowing Notes, Health Topics, or None were found).

Outcome Measures
Text
This section briefly describes the desired outcomes resulting from implementation of the recommendation, how the outcomes are
measured, and how success is identified.
Outcome measures may include (but are not limited to) patient satisfaction, health status, illness, injury, readmission, hospitalization,
length of stay (LOS), morbidity, mortality, incidence, prevalence, etc. Consider outcomes cited in the evidence for the recommendation.
Include the rationale for measuring these outcomes. How will you know your recommendations have improved the outcome?
Consider work flow when choosing outcome measures to not over-burden clinicians, families, and staff.
(If outcome assessment requires additional monitoring beyond what is already captured in normal work processes, consider using tools that have
already been validated to monitor those outcomes and processes, if available.)

Process Measures
Text
This section briefly describes the related processes necessary to obtain the outcomes above.
Process measures evaluate the way care is provided. These may include technical (e.g., procedures, therapies, wait time, cost, LOS) or
interpersonal (e.g., communication, compassion) processes. Consider processes cited in the evidence for the recommendation. Include the
rationale for measuring these processes. How will you know your recommendations have improved the process?
Consider work flow when choosing process measures to not over-burden clinicians, families, and staff.
(If process assessment requires additional monitoring beyond what is already captured in normal work processes, consider using tools that have already
been validated to monitor those outcomes and processes, if available.)
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INCLUSION CRITERIA, EVIDENCE SEARCH STRATEGY, & SEARCH RESULTS
Criteria for considering studies for this review
Types of Studies
Types of Participants
Types of Interventions
Types of Outcomes
Exclusion Criteria, if any

Study designs which were considered for inclusion in the systematic review
Patients/Population(s) which were considered for inclusion in the systematic review
(What populations were applicable to this review? For example, only pediatric studies were
planned for inclusion.)
Interventions and Comparisons which were considered for inclusion in the systematic review
Outcomes which were considered for inclusion in the systematic review
Additional criteria for exclusion that go beyond simply the opposite of the inclusion criteria

Search Strategy
Search Methods
To select evidence for critical appraisal by the group for this BESt, the databases below were searched using search terms, limits,
filters, and date parameters to generate an unrefined, “combined evidence” database. This search strategy focused on answering the
clinical questions addressed in this document and employing a combination of Boolean searching on human-indexed thesaurus terms
(e.g., MeSH) as well as “natural language” searching on words in the title, abstract, and indexing terms.

Search Databases
MedLine
via PubMed or
Ovid
CINAHL
Cochrane
Database for
Systematic
Reviews
PsycInfo
Other:

Limits, Filters, &
Search Date
Parameters

Search Terms

Keyword(s), subject,
headings, MeSH terms

Database

Limits
applied

small bowel bacterial
overgrowth, small intestine
bacterial overgrowth, SBBO,
SIBO, blind loop syndrome,
antibiotic, prophylactic
antibiotic, antibacterial
agents, or anti-infective
agents
"Intestine,
Small/microbiology"[MAJR]
AND "humans"[MeSH
Terms]) AND ("AntiBacterial Agents "[MeSH]
AND "humans"[MeSH
Terms]) AND
"humans"[MeSH Terms]
AND
Small bowel bacterial
overgrowth AND antibiotics

Cochrane
Database
for
Systematic
Reviews

2006 to
present,
English
language

PubMed

2006 to
present,
English
language

CINAHL

2006 to
present,
English
language

Publication Dates or
Search Dates
• 2006 to present
English Language
Pediatric Evidence
Only:
•X
Other Limits or
Filters:
•X

105
Copyright © 2011–2018 Cincinnati Children's Hospital Medical Center; all rights reserved.
February 26, 2018
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence |
Edward L. Pratt Research Library | Occupational Therapy & Physical Therapy | Hospital Medicine

www.cincinnatichildrens.org/evidence

Date of
Most
Recent
Search
1/1/2018

Best Evidence Statement – BESt
Search Results
The citations were reduced by eliminating duplicates, review articles, non-English articles, and adult articles (e.g., limits/filters above).
The resulting abstracts and full text articles were reviewed by a methodologist to eliminate low quality and irrelevant citations or articles.
During the course of the BESt development, additional articles were identified from subsequent refining searches for evidence, clinical
questions added to the guideline and subjected to the search process, and hand searching of reference lists. The dates of the most
recent searches are provided above.
The initial search for evidence identified 26 articles.
13 articles met the inclusion criteria above.

TEAM MEMBERS & CONFLICTS OF INTEREST
Group / Team Members
Multidisciplinary Team
Team Leader/Author: Christie Heinzman, RN, MSN, APRN-CNP – Gastroenterology Nurse Practitioner
Team Members/Co-Authors:
Conrad Cole, MD, Gastroenterology physician, Cincinnati Children’s Hospital Medical Center
Heidi Anderson, MD, Infectious Disease physician, Cincinnati Children’s Hospital Medical Center
David Haslam, Infectious Disease physician, Cincinnati Children’s Hospital Medical Center
Josh Courter, Infectious Disease pharmacist, Cincinnati Children’s Hospital Medical Center

Other Evidence-Based Care Recommendation Development Support
Content Reviewers:
Support/Consultants:
Methodologist:

Conflicts of Interest were declared for each team member and:
No financial or intellectual conflicts of interest were found.
No external funding was received for development of this recommendation.
The following conflicts of interest were disclosed:
Firstname Lastname – State found conflicts.
Firstname Lastname – State found conflicts.
Firstname Lastname – State found conflicts.
Conflict of interest declarations information is maintained in Cincinnati Children’s ePAS (electronic Protocol Administration System).

FUTURE RESEARCH AGENDA
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LEGEND EVIDENCE EVALUATION SYSTEM

(LET EVIDENCE GUIDE EVERY NEW DECISION)

Full tables of the LEGEND evidence evaluation system are available in separate documents:
• Table of Evidence Levels of Individual Studies by Domain, Study Design, & Quality (abbreviated table below)
• Grading a Body of Evidence to Answer a Clinical Question
• Judging the Strength of a Recommendation

Table of Evidence Levels (see link above for full table):
Quality Level
1a† or 1b†
2a or 2b
3a or 3b
4a or 4b
5a or 5b
5

Definition
Systematic review, meta-analysis, or meta-synthesis of multiple studies
Best study design for domain
Fair study design for domain
Weak study design for domain
General review, expert opinion, case report, consensus report, or guideline
Local Consensus

†a = good quality study; b = lesser quality study

Table of Grade for the Body of Evidence (see link above for full table):
Grade
High
Moderate
Low
Very Low
Grade Not Assignable

Definition
Good quality, High-level studies with consistent results
Good quality, Lower-level OR Lesser quality, Higher-level studies with consistent* results
Good or lesser quality, Lower-level with results that may be inconsistent
Few Good or Lesser quality, Low-level studies that may have inconsistent results
Local Consensus

Table of Language and Definitions for Recommendation Strength (see link above for full table):
Language for Strength
It is strongly recommended that…
It is strongly recommended that… not…

Definition
When the dimensions for judging the strength of the evidence are applied,
there is high support that benefits clearly outweigh risks and burdens.
(or visa-versa for negative recommendations)
It is recommended that…
When the dimensions for judging the strength of the evidence are applied,
It is recommended that… not…
there is moderate support that benefits are closely balanced with risks and
burdens.
It is suggested that…
When the dimensions for judging the strength of the evidence are applied,
It is suggested that… not…
there is weak support that benefits are closely balanced with risks and burdens.
There is insufficient evidence to make a recommendation…

EVIDENCE-BASED CLINICAL CARE RECOMMENDATION DEVELOPMENT PROCESS
The process by which these recommendation statements were developed is documented in the BESt Development Process Manual;
relevant development materials are kept electronically. The recommendations contained in this BESt were formulated by a
multidisciplinary working group, which performed a systematic search and critical appraisal of the literature using LEGEND (see section
above). The BESt has been reviewed and approved by clinical experts not involved in the development process.
Recommendations have been formulated by a consensus process directed by best evidence, patient and family preference, and clinical
expertise. During formulation of these recommendations, the team members have remained cognizant of controversies and
disagreements over the management of these patients. They have tried to resolve controversial issues by consensus where possible
and, when not possible, to offer optional approaches to care in the form of information that includes best supporting evidence of efficacy
for alternative choices.

Review Process
This Best Evidence Statement has been reviewed against quality criteria by two independent reviewers from the CCHMC Evidence
Collaboration.
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If the guideline was not externally appraised using the AGREE II criteria, delete the following sentence, list and percentages.
The guideline was also externally appraised by three independent reviewers using the AGREE instrument (Appraisal of Guidelines for
Research and Evaluation) and the results by domain are:
• Scope and Purpose
• Stakeholder Involvement
• Rigor of Development
• Clarity and Presentation
• Applicability
• Editorial Independence

XXX%
XXX%
XXX%
XXX%
XXX%
XXX%

Revision Process
The BESt will be removed from the Cincinnati Children’s website, if content has not been revised within five years from the most recent
publication date. A revision of the BESt may be initiated at any point that evidence indicates a critical change is needed.
If this is the initial development of the BESt, delete the following paragraph. If this is a revision, please include:
The most recent details for the search strategy, results, and review are documented in this BESt. Details of previous review strategies
are not documented. However, all previous citations and content were reviewed for appropriateness to this revision. Experience with
the implementation and monitoring of earlier publications of this BESt have provided learnings, which have also been incorporated into
this revision.

Review History
Date

Event
Original Publication

Outcome
New BESt developed and published

Permission to Use the BESt
Copies of this Best Evidence Statement (BESt) and related tools (if applicable, e.g., screening tools, algorithms, etc.) are available
online and may be distributed by any organization for the global purpose of improving child health outcomes.
Website address: http://www.cincinnatichildrens.org/service/j/anderson-center/evidence-based-care/bests/
Examples of approved uses of the BESt include the following:
• Copies may be provided to anyone involved in the organization’s process for developing and implementing evidence based care;
• Hyperlinks to the CCHMC website may be placed on the organization’s website;
• The BESt may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all
written or electronic documents; and
• Copies may be provided to patients and the clinicians who manage their care.
Notification of CCHMC at EBDMinfo@cchmc.org for any BESt adopted, adapted, implemented, or hyperlinked by the organization is
appreciated.

Please cite as:
Authors, Team Leader, Team Members (Year). Cincinnati Children's Hospital Medical Center: Best Evidence Statement: Title.
http://www.cincinnatichildrens.org/service/j/anderson-center/evidence-based-care/recommendations/default/, BESt number, pages 1number, Date. Hyperlink the document.

For more information
About Cincinnati Children’s Best Evidence Statements and the development process, contact the Cincinnati Children’s Evidence
Collaboration at EBDMinfo@cchmc.org.

Note / Disclaimer
This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a comprehensive
practice guideline. These recommendations result from review of literature and practices current at the time of their formulation. This
Best Evidence Statement does not preclude using care modalities proven efficacious in studies published subsequent to the current
revision of this document. This document is not intended to impose standards of care preventing selective variances from the
recommendations to meet the specific and unique requirements of individual patients. Adherence to this Statement is voluntary. The
clinician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding any specific care
recommendation.
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Evidence Table for Included Articles
Study Type
Study Citation

N
Sample Size

(i.e., articles meeting inclusion criteria; Dimension 1 for each outcome)

OUTCOME OR TABLE TITLE
Population
Intervention / Comparison Groups

Outcomes

(Setting, Patients)

Evidence
Level

Significant Results and Conclusions
Including estimates with associated precision (e.g., Odds Ratios or NNT with Confidence Intervals) as well as Limitations / Risk of Bias, Gaps, Applicability, Consistency, or other Notes

•
•
•
•
•

•
•

•
•

•
•

•
•

•
•

•
•

•
•

•

**See Appendix F, Summary of
Pediatric Literature and Appendix
H, Summary of the Adult Literature
for Critical Appraisal of the
included articles.
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